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INTRODUCTION  
 
In the worldwide, sexual transmitted infections (STIs) represent an important public health 
problem with an estimated million of new cases of infections occurring each year. Young 
people account for only 25% of the sexually active population which accounts for almost 
50% of newly acquired STIs (Siracusano et al., 2014). These consist in bacterial, fungal 
and protozoal infections that can be treated with appropriate chemotherapeutic agents or, 
as reported, can trigger viruses often leading incurable STIs (Gewirtzman et al., 2011).  
Microorganisms causing chronic inflammatory diseases have become to be increasingly 
investigated in the last decade as possible cancer initiators/promoters (Idahl et al., 2011).  
So far, the most common STIs are those caused by Human papillomavirus (HPV) and 
Chlamydia trachomatis (CT). However, epidemiological data on CT prevalence and 
CT/HPV co-infection are not yet well defined in Italy (Bellaminutti et al. 2014, Panatto et 
al 2014; Seraceni et al. 2014). 
 
HUMAN PAPILLOMAVIRUS  
 
Characteristics 
Papillomavirus belong to the Papovaviridae family, which includes 16 different genera, 
five in humans (Alphapapillomavirus, Betapapillomavirus, Gammapapillomavirus, 
Mupapillomavirus, Nupapillomavirus), that have different types, life-cycle characteristics 
and disease associations, based on DNA sequence analysis. Of these, The Alpha genus 
contains the mucosal type viruses that cause genital warts or lesions associated with the 
development of cervical neoplasia and cancer at low-risk (LR-HPV) and high risk (HR-
HPV), respectively. The Beta genus, instead, contains those genotypes that are associated 
with the development of cutaneous cancers. Their possible role in cancer progression in the 
general population is currently unresolved (Bernard et al., 2013) (Figure 1).  
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Fig. 1: Evolutionary Relationship between Human Papillomaviruses. 
Human Papillomaviruses comprise five evolutionary groups with different epithelial tropisms and disease 
associations. (Modified and adapted from de Villers et al. 2004). http://www.bioafrica.net/rega-
genotype/html/subtypeprocesshpv.html  
 
These viruses contain a double strand DNA with 8000 pb approximately arranged in an 8 
well defined genes. All members of the HPV family have a typical genomic organization 
with 8 or 9 open reading frames (ORFs) on the same DNA strand. The HPV genome is 
divided into three regions: six early genes (E) are involved in virus expression, replication 
and survival and two other genes called late genes (L), are involved in virus assembly; 
finally, the long control region (LCR), which is localized between ORFs L1 and E6, 
contains most of the regulatory elements involved in viral DNA replication and 
transcription. The designations E and L refer to the phase in the viral life cycle when these 
proteins are first expressed (Figure 2). E2 regulates early gene promoter and together E1 
forms a heterodimer complex to control virus DNA replication. E4 may mediate the release 
of viral particles by destabilization of the cytokeratin network, whereas E5 stimulates 
mitogenic signals of growth factors. E6 and E7 are oncoproteines capable of deregulate 
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fundamental cellular events, such as cell cycle, DNA repair, senescence, apoptosis and 
differentiation, facilitating the accumulation of DNA damage and the progression towards 
malignancy. If the immune system can eliminate quickly the HPV-infected cells, E6 and 
E7 do not manage to accumulate chromosomal abnormalities and acquire a malignant 
phenotype, despite their transforming properties. Therefore, the establishment of a chronic 
infection is a fundamental and crucial event for the development of HPV-associated 
malignant diseases. Host and environmental factors significantly contribute to the 
chronicity of HPV infection, despite HR-HPV E6 and E7 target cellular pathways related 
to innate and adaptive immunity. L1 and L2 are major and minor capsid protein, 
respectively and L1 is the component of the HPV prophylactic vaccine. 
HPV infects the epithelium of the cervix and their replication is closely linked to the 
differentiation of the epithelium (Doorbar et al., 2012; Tommasino, 2014). 
 
 
Fig. 2: The genome organization of HPV16 is typical of the high-risk Alphapapillomaviruses (Agnes and 
Gunnar, 2008). http://.medscape.com. 
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These virus, of which have been identified more than 150 HPV genotypes, have selective 
tropism for cutaneous or mucosal epithelia and are divided into two groups: LR-HPV and 
HR-HPV, as previously described. LR-HPV that cause benign lesions asymptomatic that 
may resolve spontaneously in 3-4 months, are named papillomas (small wart-like 
neoplasias), which are due to sexual transmission of the virus, occur in 
male and female genitals, urethra, anus and perianal area and rarely lead to cancer. HPV6 
and HPV11, two among the most common LR-HPV, are associated with 90% of genital 
warts and recurrent respiratory papillomas. HR-HPV cause malignant cellular 
transformation and develop into large tumors, characterized by squamous intraepithelial 
lesion (SIL) that occur with rounded cells with nuclear and perinuclear (koilocytosis) 
atypia. Nuclear abnormalities, such as enlarged nuclei, hyperchromasia and mitotic cell 
features can also be found.  
HPV infections are also common in intraepithelial cervical neoplasia (CIN); these are 
characterized by the presence of koilocytosis and are divided into low-grade (LSIL) and 
high-grade (HSIL). According to the histological classification there are three degrees of 
CIN: CIN 1 (mild), corresponds to LSIL, CIN2 and CIN3 correspond to moderate and 
severe HSIL, respectively. HPV infection is the major cause of the CIN development. 
Despite women’s frequent exposure to HPV, the development of cervical cancer (CC) is 
relatively rare. Most low-grade cervical abnormalities, such as CIN1, are associated with 
benign viral replication, and spontaneously regress without requiring treatment (Martin et 
al., 2011). Studies in women have shown CIN1 regression rates of up to 70–80%; however, 
in adolescents and young women under 25 years, more than 90% show regression (Cox et 
al., 2003; Moscicki et al., 2004; 2010). In contrast, HSIL, specifically CIN3, has a much 
greater potential to progress to invasive cancer (progression rates of between 0.2–4% 
within 12 months) (Fearly et al., 2010). HR-HPV genotypes identified as causing CC 
belong to groups based on epidemiologic and mechanistic evidence of their carcinogenicity 
(Rosales and Rosales, 2014). Twelve HPV genotypes (HPV16,-18,-31,-33,-35,-39,-45,-
51,-52,-56,-58 and-59) are classified as “carcinogenic to humans” (Group 1), HPV68 as 
“probably carcinogenic” (Group 2A) whilst others seven HPV genotypes, as “possibly 
carcinogenic” HPV26,-53,-66,-67,-70,-73,-82 (Group 2B) (IARC, 2012) (Figure 3).  
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Fig. 3: The HR Alpha types have been clearly linked with the development of squamous cell carcinoma 
(SCC) and adenocarcinoma (AC) of the cervix. IARC category 1 and 2A HPV genotypes are classified 
(respectively) as carcinogenic and possibly-carcinogenic. Despite limited epidemiological data, the 2B 
classification is proposed for genotypes that are probably carcinogenic because of their close phylogenetic 
relationship with the established carcinogenic types. HPV genotypes in category 3 are considered non-
carcinogenic (Doorbar et al., 2012). 
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HPV infection and Life Cycle 
 
So far, most of the biological studies concerning the clear association of mucosal HR-HPV 
genotypes with human carcinogenesis (Zur Hausen, 2002), have been focused on these 
types. HPV infects the cells of the basal layer, where it is present at a relatively low copy 
number. The HR-HPV life cycle is tightly linked to the differentiation programme of 
stratified epithelia. HPV initiates the productive phase of its life cycle, that is characterized 
by vegetative viral DNA replication, when cells leave the basal layer of the epithelium. 
During this phase, the HPV genome is amplified to more than 1000 copies per cell and 
subsequently, the expression of late genes starts and viral particles are produced and 
released. In contrast to mucosal HPV types, nothing is known about the life cycle of the 
majority of HPV types that belong to the Beta and Gamma genera. Studies of mucosal 
HPV types have shown that the first step in HPV infection is the interaction of the viral 
capsid with the cytoplasmic membrane of cells at the basal layer of the epithelium 
(Tommasino, 2013). This event is mainly mediated by the major capsid protein, L1, which 
interacts with the cell surface via heparan sulfonated proteoglycan (HSPG) (Doobar et al., 
2012). It is also possible that the viral particles bind to another component of the cellular 
membrane, the integrin α6, proposed as a secondary cellular receptor for HPV particles 
(Evander et al., 1997) even if, the precise nature of the entry receptor remains somewhat 
controversial (Doobar et a., 2012; Tommasino, 2013).  
The internalization of HPV16 particles, after binding to the cellular membrane, is mediated 
by a clathrin-dependent endocytic pathway (Day et al., 2003). Additional findings indicate 
that other mucosal HPV types may use different endocytosis pathways (Bousarghin et 
al.,2003). It is also highly likely that the minor capsid protein, L2, plays a role in 
membrane binding and cellular internalization. In fact, in vitro assays anti-L2antibodies 
against specific linear epitopes are able to block the internalization of L1/L2 virus-like 
particles (Kawana et al., 2001; Gambhira et al., 2007) and the annexin A2 hetero tetramer 
contributes to HPV16 infection in an L2-dependent manner (Woodham et al., 2012). 
Recently, Surviladze and colleagues have presented evidence of a novel mechanism of 
viral entry, observing that HPV16 particles, after binding to the cell surface, are released as 
a soluble complex with HSPGs and growth factors. The growth factors mediate the 
interaction of the soluble complex with their cognate receptors, facilitating the 
internalization of the viral particles (Surviladze et al., 2012). 
10 
 
Natural history of HPV infection 
 
The HPV lifecycle is closely linked to stratified epithelium differentiation (Pyeon et al., 
2009). HPV virions infect the basal epithelium through micro-abrasions in the epidermis. 
The modality of virus invasion is still not fully understood, but several receptors, including 
heparan sulphate proteoglycans and alpha-6 integrin, have been associated with this 
process (Doobar, 2006). Upon migration to the basal cell nucleus, the viral genomes are 
established as episomes, the early promoter are activated and finally resulting in low levels 
of viral synthesis. During normal epithelium differentiation, the daughter cells migrate 
from the basal layer upwards and undergo terminal differentiation. Viruses finally reach 
the epithelial surface where they form a cornified layer of dead cells, which are eventually 
eliminated (Figure 4).  
 
 
Fig 4: The location in the squamous epithelium of the main stages of the papillomavirus life cycle. Cervical 
stratified squamous epithelial cell architecture and the expression of HPV proteins after infection. Daughter 
cells of epithelial stem cells divide along the basement membrane and then mature vertically through the 
epithelium without further division (right side). (Muñoz et al, 2006) 
http://www.nature.com/nri/journal/v4/n1/fig_tab/nri1260_F2.html  . 
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In HPV-infected differentiating cells, the late promoter is activated, leading to the 
vegetative state of the HPV lifecycle (Longworth et al., 2004). During this phase, high 
levels of viral DNA are replicated, enveloped into capsids and released from the cell. To 
maintain viral synthesis in the epithelium, the virus takes advantage of the host cell 
replication system. Consequently, the HPV oncoproteins E6 and E7 come into play, 
maintaining the cell cycle and preventing terminal differentiation. The HPV infected cells 
move up through the epithelium and the viral infected basal cell layer is maintained with a 
low level of viral DNA synthesis. This typically occurs in LSIL disease. HSIL lesions, 
such as CIN3, are typically associated with HPV DNA that has integrated into the host 
genome. Viral integration often occurs in the E1 and E2 regions downstream of the late 
genes. This can result in disruption and loss of these late genes, with subsequent loss of 
control of oncogene expression by the E2 viral gene (Woodman et al., 2007). To maintain 
the HPV infection, HR-HPV genotypes produce E6 and E7 oncogenes, which interfere 
with critical cell–cycle checkpoint pathways and proteins, namely p53 and retinoblastoma 
(Martin et al., 2011) (Fig. 5). 
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Fig. 5: A: The cervical squamocolumnar junction. The basal cells rest on the basement membrane, which is 
supported by the dermis. Normal squamous epithelium differentiates as shown. The transformation zone is 
the most common site for the development of CC. Prophylactic vaccines induce L1- or L2-specific antibodies 
that neutralize the virus. B: After the HPV infection of basal keratinocytes, the early HPV genes E1, E2, E5, 
E6 and E7 are expressed (red nuclei) and the viral DNA replicates. LSILs support productive viral 
replication. In the upper layers of epithelium the viral genome is replicated further, and E4 (green 
cytoplasm), L1 and L2 (orange nuclei) are expressed. L1 and L2 encapsidate the viral genomes to form 
progeny virions in the nucleus. The shed virus then re-initiates infection. C: A significant fraction of HR-
HPV infections progress to HSILs, which show a lesser degree of differentiation. HSILs are effectively 
treated by loop electrosurgical excision (LEEP). Pap screening and HPV tests can be used to detect SILs. 
D:The progression of untreated lesions to micro invasive and frankly invasive cancer is associated with the 
integration of the HPV genome into the host chromosomes, loss of E2 and up-regulation of viral oncogene 
expression and genomic instability. These cancers are treated with surgery, chemotherapy or radiotherapy 
with limited success. Therapeutic vaccines and immune stimulants such as imiquimod can potentially induce 
an infiltration of T cells specific for the early viral antigens and clearance. (Roden and Wu, 2006). 
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Epidemiology 
 
The worldwide prevalence of HPV infection in women with normal cytology is around 11–
12%, with the majority prevalence in sub- Saharan Africa (24%), Eastern Europe (21%) 
and Latin America (16%) (Bruni et al, 2010). In women less than 25y, HPV prevalence has 
been observed highest, decreasing average with progression of age in many populations, 
some of which have a secondary peak in peri-menopausal or early menopausal time (Denis 
et al., 2008; Ali et al., 2013; Melo et al., 2014; Cuzicke et al., 2014). In China, the 
prevalence is instead relatively age independent. The explanation of these difference 
prevalence pattern and the clinical significance is not understood. Globally, the five most 
prevalent types are HPV16 (3.2%), HPV18 (1.4%), HPV52 (0.9%), HPV31 (0.8%) and 
HPV58 (0.7%) (Bruni et al, 2010). Prevalence increases in women with cytologic cervical 
pathology in direct proportion to the severity of the lesion, reaching around 90% in women 
with CIN3 and invasive CC. In fact, 100% of all CC has been found to be HPV positive. 
Of note, the proportion of HPV positive women in whom HPV16 is greatly detected, 
increases with lesion severity (Bosch et al., 2013). 
Infection with HR-HPV types is recognized as one of the major causes of infection-related 
cancer worldwide. A strong evidence for a causal etiology with HPV has been stated by the 
IARC for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including 
base of the tongue and tonsils), which has estimated the overall number of cancers 
attributed to HPV and classified by geographic region.  
The prevalence of HPV infection with specific genotypes differ by age and area. In 2008, 
there were estimated in the world 12.7 million new cancers, of which 700,000 with an 
HPV-associated cancer site. 610,000 of these were attributable to HPV only (Ferlay et al., 
2010) which alone represents 4.8% of the total burden of cancer worldwide that varies 
widely by geographic region, ranging from 1.2% in Australia and New Zealand to 14.2% 
in sub-Saharan Africa and 15.5% in India.  
Of note, 80.6% of the total number of cases attributable to HPV occurred in 
underdeveloped countries (6.9%) compared with 2.1% in more developed countries. In the 
world, CC resulted the third most common female cancer, (approximately 86% of these 
cases occurred in underdeveloped country), with a strong association between CC 
incidence and level of development.  
In underdeveloped countries, the incidence and mortality rates tend to be higher compared 
to developed and after 5-year relative survival, in these different conditions is observed a 
similar pattern 20% vs 65%, respectively. Global maps of CC rates show patterns of 
14 
 
variation largely consistent with level of develop. According to a meta-analysis regarding 
the prevalence of HPV genotypes in women with normal cytology, HR-HPV16, although 
high and variable across world regions, resulted the most prevalent genotype (22.5%). 
Others HPV genotypes highly prevalent resulted, HR-HPV18,-52-,31-58,-39,-51,-56 and 
LR-HPV6 (Bruni et al., 2010). 
Italy, mirrors the world trend, with a strong variability of HPV prevalence by age and area 
(Agarossi et al., 2009; Giorgi Rossi et al., 2010, Giuffrè et al., 2010; Bellaminutti et al., 
2014; Carrozzi et al., 2014). HPV16 resulted the most common genotype in our country 
(Giorgi et al., 2011; Bianchi et al., 2013; Carozzi et al., 2014).  
 
Immunopathogenesis of HPV  
 
The most frequent HPV infections recover spontaneously, within two years from infection 
and without any clinical manifestation by immune-competent individuals; consequently the 
immune system is able to effectively eliminate virus-infected cells. However, the natural 
immune response may be insufficient, not allowing the infection resolution. The virus does 
not cause viremia, or systemic infection. The virus absence in the blood and its 
characteristic intracellular replication and not accompanied by cell lysis, involves the 
inability of the immune system to mount a strong antibody response or to induce 
inflammation (Rosales and Rosales, 2014). 
The initial inflammatory response induced by tissue damage leads to infiltration of immune 
cells mainly neutrophils, followed by macrophages and later lymphocytes, that recognize 
“danger” viral molecules detected by pattern recognition receptor (PRR), such as Toll like 
receptors (TLR) (Kawai and Akira, 2011). The immune response innate induces the lysis 
of the infected cells and the production of cytokines pro-inflammatory such as IL-1β, IL-
6,IL-8, IL-12 and INF-α,-β,-γ, to activate natural killer cells (NK) and other immune cells 
(Woodworth, 2002).  
T cells, activated by recognition of viral proteins, induce the growth and maturation of B 
cells. These cells, together with the cell-mediated response, are necessary to ensure an 
effective protection against the virus. The induction of neutralizing antibodies specific for 
L1 and L2 proteins viral capsid, is critical to prevent the onset of symptoms and the 
entrance of the virus into cell. 
Infiltrations of CD4+ (Helper) and CD8+ (Cytotoxic) T cells that are absent in persistent 
lesions, has been detected in spontaneously regressing HPV-related lesions, indicating that 
the adaptive immune response against the virus is important and for the most cases 
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effective. This adaptive response comprises elements of humoral and cellular immunity 
(Stanley, 2006). 
The humoral immune response, in the majority of patients with HPV infections, is 
characterized, in the first stage of infection, by antibodies against different HPV proteins 
such as L1, E2, and E4 proteins. Antibodies against E6 and E7 oncoproteins can be 
detected in low- and high-grade lesions, when viral DNA gets integrated into cellular 
genome. However, this antibody response is usually weak and variable. It does not seem to 
protect from future re-infections (Tjiong et al., 2001) and the seropositivity seems 
depending on the site of the cancer around the anogenital area, indicating that cancer 
development may lead to changes in antibody responses in a site-specific fashion (Carter, 
2001). Thus, humoral responses are not enough efficient to eliminate established HPV 
lesions. In addition, antibody titers can persist for many years even after the virus is 
cleared, so seropositivity is a useful marker for past infection rather than current infection. 
Cell-mediated immune responses are more important in clearing HPV-related lesions. T 
cells HPV-specific are generated to fight and eliminate infected cells; thus both, CD4+ and 
CD8+ T cells and also responses that include HPV specific regulatory T cells (Treg) that 
inhibit cytotoxic activity (Welters et al., 2003), are important for elimination of HPV 
infection. In fact, T cell responses to viral proteins are present in patients who successfully 
eliminated previous HPV16 infections. Moreover, T cells, with a predominance of Th1 
cytokines, were observed in high ratio during regressing lesions. In contrast, in patients 
presenting CIN or CC, a deficient T cell response with a strong shift to Th-2 cytokine 
profile, are observed in persistent lesions. Thus, an efficient cytotoxic cell-mediated 
immune response is critical for elimination of HPV-related lesions. Unfortunately the virus 
has also evolved mechanisms to interfere with the immune response (Rosales and Rosales, 
2014). 
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HPV Strategies for Evading Host Immune Response 
 
HPV has evolved several mechanisms to evade the immune system. In the areas where 
HPV replication takes place, the immune surveillance is poor. In the stratified squamous 
epithelium of the uterine cervix, surveillance by dendritic cells (DCs) greatly declines 
towards the keratinized layers. 
The keratinocytes infected by HPV express a low load of viral proteins and thus, do not 
induce their lysis. Expression of viral gene products up-regulates progressively with 
differentiation and upward migration of keratinocytes Moreover, HPV down-regulates, by 
E6 and E7 oncoproteins, the expression of major histocompatibility complex (MHC) class 
I molecules, TLR9, and cytokines such as, interferon and interleukin (IL-8) (Stanley, 
2006). 
In this way, HPV late proteins, which are the most immunogenic, are expressed at areas of 
poor immune surveillance (Figure 5). In addition, new virions are released through the 
normal rupture of surface epithelium, reducing any possible inflammatory response and 
avoiding uptake by DCs. Therefore, HPV replication is a local phenomenon with minimal 
activation of the immune system. Moreover, a reduced inflammation state is found in 
persistent lesions and in tumors. This condition correlates with a change in the cytokine 
profile produced at the site of infection.  
A shift to Th2 cytokines is also common in persistent lesions (Bais et al., 2007; Rosenthal 
et al., 2012). This leads to an inhibitory state for helper CD4+ T cells. In addition, Tregs 
have been found infiltrating tumors, especially in the early stage of tumor progression 
(Piersma et al., 2008). Thus, any therapeutic approach must be able to induce a strong 
HPV-specific immune cell response that involves CD4+, CD8+ cells, and Th1 type 
cytokines. 
However, HPV has also evolved mechanisms to avoid both initial detection and to interfere 
with adaptive response, that allows the virus to persist and lesions to progress into cancer 
(Figure 6). 
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Fig. 6: HPV-mediated effects on the host immune response.  
A: Immune evasion mechanisms employed by a HPV-infected cell are polarization of T cell subtypes, 
inhibition of the CTL (C8+) response and modulation of APC trafficking.  
B: Immune evasion mechanisms of HPV-driven malignantly transformed cells include recruitment of 
immunosuppressive cells, leading to immunosuppressive cytokine production. (Grabowska et a., 2012). 
http://openi.nlm.nih.gov/ 
 
 
HPV infection and Cervical Cancer 
 
HPV is a sexually transmitted agent deemed a cause of CIN and invasive CC in worldwide. 
Currently it is widely accepted that specific genotypes of HPV are potentially oncogenic 
and are associated with virtually all cases of CC and, to a lesser extent, with cancers of the 
vagina, vulva, anus, penis, skin and oropharynx (Trottier et al., 2006; Parkin et al., 2006; 
Shukla et al., 2009; Moody et al., 2010).  
Over than 100 HPV types classified into HR-HPV are linked to both to tumor precursor 
lesions and to the progression of invasive CC (Simonetti et al., 2009), the second most 
common cancer among women (Arbyn et al., 2011) and the seventh in the world (Forman 
et al.,2012). Persistent infection with one of the oncogenic HPV genotypes is required to 
cause CC (Walboomers et al. 1999; Bosch et al., 2002). 
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HPV must be persistent within the host epithelial cells as a preliminary step toward 
advanced neoplastic changes. This process takes years, if not decades, to occur after initial 
HPV infection. Persistent infection, with HPV genotypes with high oncogenic potential, 
increases the probability of ICC following an extended period of latency. The integrity of 
the cell-mediated immune response against HPV is an important factor for healing and 
prevention of the reactivation of the latent infection (Fernandes et al., 2013; Stanley, 
2006). 
Recent studies seem to suggest that these changes may develop more quickly than 
previously thought. Winer et al., followed women after initial HPV infection for the 
development of CIN 2/3 and approximately 27% of women with an initial HPV16 or 18 
infection progressed to CIN 2/3 within 36 months (Winer et al., 2005). A second study, 
performed on a large health maintenance cohort, found that approximately 20% of women 
30y or older, who were initially infected with HPV16, developed CIN3 or CC within 120 
months, while women who had an initial HPV18 infection, had approximately a 15% risk 
(Khan et al., 2005). 
The strong correlation between infection with HR-HPV and LSIL, HSIL, and CC suggests 
that HPV DNA testing would be an useful tool for the management of women with 
abnormal Pap test results, especially in the case of those with equivocal test results. In the 
case of an equivocal Pap test result, HPV DNA testing can help determine whether the 
individual should be referred for colposcopic assessment (Cox et a., 2003). 
Accumulating evidence suggests that a combination of screening strategies is needed to 
detect as early as possible HPV induced lesions CC.  
Epidemiological studies in HPV infected females have provided important clues about a 
spectrum of cofactors that can increase the carcinogenic HPV potential. Presumably, 
cervical infections with other pathogens, exposure to physical and chemical agents, 
hormonal factors and Chlamydia trachomatis (CT) itself, as previously demonstrated 
(Smith et al, 2002; de Abreu et al., 2012). Notably, the infections caused by these two 
pathogens are often associated with an intense chronic inflammatory response and 
ulcerations in the cervical epithelium (Scott et al., 1999; Adefuye and Sales, 2012, Silva et 
al., 2014). 
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CHLAMYDIA TRACHOMATIS 
 
Characteristics  
 
The Chlamydiaceae are a family of ubiquitous gram-negative, aerobic, obligate 
intracellular bacteria present in the environment including aquatic.  
Once considered viruses, they grow in eukaryotic cells and are responsible of a wide range 
of diseases in human and animals. A recent revision has taxonomically re-classified the 
group in 4 distinct families (Chlamydiaceae, Simkaniaceae, Parachlamydiaceae and 
Waddliaceae) based on > 90% 16S rRNA identity and a single genus which include the 
different species. C. pneumoniae (CP) and C. trachomatis (CT) are common pathogens in 
humans, but the routes of transmission, susceptible populations and clinical presentations, 
differ markedly, although have a common developmental cycle (Contini and Seraceni, 
2012). Currently, there have been described 11 species of Chlamydia. Most are able to 
infect several host species and anatomical sites. CT, the most medically significant 
chlamydial species, is a human-specific microorganism capable of produce pulmonary, 
ocular and genital pathologies in either neonates or adults (Bachmann et al., 2014) (Figure 
7). 
 
 
Fig. 7: Phylogenetic reconstruction based on almost complete 16S rRNA genes from type strains of 
established Chlamydiaceae spp., including the recently proposed new species C. avium and C. gallinacea 
(Sachse et al. Systematic and Applied Microbiology, 2015). 
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Ocular infections caused by CT are the leading cause of preventable blindness (trachoma) 
(Lu et al., 2013) or lymphomas (Contini et al., 2009; Contini et al., 2013) whereas genital 
infections are known to have adverse effects on female reproduction (Shao et al., 2013).  
In women, due to the high frequency of the asymptomatic phase, CT can lead to pelvic 
inflammatory disease (PID), infertility, ectopic pregnancy and chronic pelvic pain. 
(Haggerty et al., 2010). Infections by CT are also known to facilitate rheumatic disease 
(Gerard et al., 2010; Carter et al., 2012; Zeidler and Hudson, 2014).  
CP is the other human chlamydial pathogen prevalently associated to respiratory infections 
as community-acquired pneumonia worldwide (10–20%) and asthma (Blasi et al., 2004; 
Stocks et al., 2004; Hahn et al. 2012; Asner et al., 2014). Moreover, evidence seems to 
suggest that CP is also linked to cardiovascular, rheumatic and neurologic disease 
(Witkiewicz et al., 2005; Fernandez et al., 2005; Contini et al.; 2010; Contini et al., 2011). 
The least five other Chlamydia species have a broad host-range in animals. Chlamydia 
psittaci is primarily a pathogen of avian species that causes respiratory diseases (interstitial 
pneumonia transmitted by birds) which usually occur through inhalation of the organism 
when it is dispersed in the air as fine droplets (aerosol) or dust particles (Moroney et al., 
1998; Van Droogenbroeck et al., 2009). 
CT have extremely small circular genome (1042 kbp), which contains also a cryptic 
plasmid (length 7500 bp) linked to virulence that can contribute, to the regulation of 
chlamydial chromosomal gene expression, by its transcriptional activity (Carlson et al., 
2008). A detection of cryptic plasmid’s nucleic acid, is utilized for diagnostic purposes 
(Ljubin-Sternak and Meštrović, 2014) and usually can detect all variants discovered such 
as Sweden mutation (Paavonen, 2012). 
CT has tropism for conjunctival and genitals mucous membranes, where can lead to 
diseases with chronic inflammation.  
According to different immunoreactivity, 19 human serotypes and related variants (A, 
B/Ba, C, D/Da, E, F, G, Ga, H, I/Ia, J, K, L1, L2, L2a and L3) have been identified by 
using mono or polyclonal antibodies directed against epitopes of the major outer protein 
membrane (MOMP). These serotypes are closely related to the genotype, which is based 
on the ompA gene (encoding the protein MOMP) (Wang et al., 1985; 1991; Hsu et al., 
2006) and can be divided into three serogroups: the B group (serotypes B, Ba, D, Da, E, 
L1, L2 and L2a); the intermediate (I) group (serotypes F, G and Ga); and the C group 
(serotypes I, Ia, J, K, C, A, H and L3) (Bax et al., 2013). In contrast with the individual 
serotypes, that possess a certain correlation with the disease and the affected tissues, the 
serogroups do not correlate with either tissue tropism or the biological properties of the 
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organism. Therefore, based on the pathogenic potential, serotypes A, B, Ba and C are 
commonly associated with the development of trachoma, chronic eye condition, while D to 
K serotypes, are responsible of urogenital infections as well as neonatal conjunctivitis and 
pneumonia. The serotypes of lymphogranuloma venereum (LGV), L1 to L3 and L2a, are 
responsible of most invasive urogenital diseases (Dean, 1997; Gomes et al., 2006). 
Additionally, it seems that the infections with CT serovars G, I and D are associated with 
cervical squamous cell carcinoma and chronic infections with serotype K, in women, have 
been recognized as a cause of infertility (Marrazzo & Stamm, 1998; Koskela et al., 2000; 
Morre et al., 2000; Anttila et al., 2001). The CT serotypes most commonly isolated from 
patients are: E (50%), F (20%) and D (10%). According to recent findings, F serotype 
seems be responsible of more severe infections, whilst E of asymptomatic infections 
(Choroszy-Król et al, 2012). 
 
CT infection and Cell Cycle 
 
The intracellular growth cycle of the Chlamydiae is complex and several growth options 
are possible, depending on the host-cell type, the particular environmental conditions in the 
host cell and the nature of tissue that is being affected.  
Chlamydiae, have a characteristic biphasic growth cycle within a eukaryotic host cell, 
during which infectious, elementary bodies (EBs, 0.3–0.6 mm diameter) differentiate into 
the metabolically active but non infective reticulate bodies (RBs, 0.6–1 mm diameter), that 
divide by binary fission within the host, derived vacuoles named Chlamydial inclusions. 
After 48–72 h, RBs multiply by binary fission and reorganize into EB, which are released 
after host cell lysis. In vitro, this orderly alternation between EB and RB in life cycle 
development usually take place in 72 h, ranging from 36 to 96 h to complete, depending on 
each species and in the number of inclusions per host cell (from one in CT infected cell, to 
several inclusions for the others Chlamydiae). Under in vitro conditions with adverse 
factors, e.g., penicillins or INF-γ, RBs block division and maintain a stable association 
with the infected cell and become the aberrant or persistent bodies with enlarged forms, 
altered gene expression profile and multiple nucleoids, instead of undergoing rapid 
replication and differentiating into infectious EBs (Figure 8) (Contini and Seraceni, 2012). 
Although the life cycle of Chlamydiae is well characterized by microscopy, the signals that 
trigger interconversion of the morphologically distinct forms are not completely known 
(Beatty et al., 1994; Dautry-Varsat et al., 2005). However, EBs are no longer considered as 
inert organisms. The discovery that EBs can translocate stored proteins into the host under 
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distinct signaling pathways is further evidence that the entry process results from a 
dialogue between the bacteria and the host, although many features including EB protein 
attachment to target cells, remain to be clarified or discovered (Dautry-Varsat et al., 2005; 
Wuppermann et al., 2008). During chlamydial cell cycle, a stop in development may lead 
chronic infection, characterized by high transcriptional activity with aberrant bodies 
formation (Gerard et al., 2013). These events, reversible, constitute the basis of clinical 
persistence leading to chronic sequelae. 
Moreover, aberrant forms of RBs, with reduced MOMP and lipopolysaccharide (LPS) 
antigens, persist with high production of chlamydial heat shock protein 60 (Hsp60) can 
induce inflammation and scarring, classic characteristics of chronic infection (Malhotra et 
al., 2013). The virulence of these microorganisms is principally due to components of the 
outer membrane, inclusion proteins and polymorphic membrane proteins, (pmp) related to 
the third type secretion system (TTS), to different secretory proteins (e.g. 
glycosyltransferase), chromosomally encoded and especially to extrachromosomal factors, 
specifically plasmids (Pawlikowska-Warych et al., 2015), capable to define the outcome of 
infection and disease severity. Multiple types of genetic variation are found in CT that 
impact variability and expression of virulence factors, such as high degree of variability in 
the exposed portions of MOMP, polymorphic TTS effectors, and amino acid substitutions 
in pmp autotransporters (Abdelsamed et al., 2103). These strategies have been 
demonstrated to foster chlamydial intracellular survival, aid in the evasion of the host 
immune system, and form the basis for distinct chlamydial disease variations in host tissue 
tropism (Byrne, 2010). Host genetics also play a role in the disease severity. For example, 
women who carry specific HLA DQ and IL-10 promoter alleles that modify host immune 
response were found to develop TFI more frequent than control group (Kinnunen et al., 
2002). 
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Fig. 8: Chlamydia life cycle with main morphological and metabolic features of normal productive vs. 
persistent CT infection.  
A: schematic description of persistent life Chlamydia arrested at partially known state of the normal life 
cycle.  
B: the morphologies, the results of culture-based detection of Chlamydia, their metabolic state, their gene 
expression profiles, and energy supply of Chlamydia during productive infection and in a persistent state.  
+ indicates detection; −indicates lack of the corresponding messenger RNA (Zeidler and Hudson, 2013) 
 
 
Epidemiology 
 
The WHO estimates that, each year, CT infections are diagnosed over 90 million new 
cases (Kucinskiene et al., 2006). A 2012 report has revealed that in United States occur 
over 1 million new cases (rate 456.7 per 100,000 people) for year (CDC, 2012). In the 
developed countries, CT prevalence is high (3-6%) especially in health young heterosexual 
adults under 25y, especially those who are sexually active (Goulet et al., 2010; Eggleston 
et al., 2011). Urogenital chlamydial diseases are common in young population and tightly 
associated with sexual behavior. Other than age, other risk factors such as STDs co-
infection, new o multiple sexual partners, oral contraceptive use, are important in the 
pathogenesis of this pathology. CT prevalence in the world varies among different types of 
persons and depending on laboratory techniques used for microorganism detection. These 
differences could represent real differences in sexual behaviours patterns and CT control 
efforts, but might also result from different study design and participation rates. Paavonen 
(2012), in a review reported that European prevalence among asymptomatic women varies 
A B  
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from 1.7% to 17%, while Ljubin-Sternak and Meštrović revealed a higher prevalence 
(35.3%), in symptomatic patients (18-25y) (Ljubin-Sternak and Meštrović .2014). A large 
meta-analysis from 11 EU/EEA countries and 14 studies from five other high income 
countries, reported on young women sexually active people (18–26y), a CT prevalence 
from 3.0–5.3% (Redmond et al., 2015). 
In Italy, Italian Institute of Health reported an overall prevalence in women of 2.3% which 
was estimated approximately highest in subjects less 25y compared to over 25 (7.9% vs 2.5 
%) (Salfa et al., 2014). 
 
Immunopathogenesis of CT infection 
 
CT causes clinically unapparent infections of the upper genital tract that may result in 
significant damage to the reproductive organs, such urethritis, mucopurulent cervicitis, 
plasma cell endometritis, salpingitis (Paaovonen, 2012). CT infections increase the risk for 
tubal factor infertility and can lead to pelvic inflammatory disease (PID), infertility, ectopic 
pregnancy and chronic pelvic pain (Haggerty et al., 2010) and have been also linked to 
other adverse pregnancy outcomes, including chorioamnionitis, placemtitis, premature 
rupture of membranes and preterm birth (Rours et al., 2011). Vertical transmission from 
the genital tract can cause conjunctivitis and pneumonitis in new-borns (Paaovonen, 2012). 
The clinical course is usually subacute and poorly symptomatic, but the microorganisms 
are rarely detected in patients without clinical signs of infection. In fact, most CT 
infections are symptom-free or paucisymptomatic, remaining undetected and thus 
untreated for a prolonged period with the possibility of developing chronic infections 
because of spreading via monocytes and can cause local and systemic infections. CT is 
also a potent immunogen, stimulating the immune processes of microorganisms. 
In the course of CT infection, the response mechanisms involved are: non-specific, 
specific, humoral and cellular. Chronic infection is characterized by maintenance of 
microorganisms in the host cell. Inflammation occurs in a less time period and with 
increased intensity and evokes a rapid immune response of lymphocytes, previously 
sensitized (Choroszy-Król et al., 2012) (Figure 9). 
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Fig 9: Immune protection against chlamydial infection in the female genital tract. Innate, humoral, and cell-
mediated immunity act in concert to protect against CT infection of non-immune host genital epithelial cells 
and local innate immune cells in the female genital tract (FGT). 
Innate: The epithelial barrier is relatively ineffective at protecting against Chlamydia as this mucosal 
pathogen has a myriad of mechanisms to evade barrier protection. A mucus layer containing a variety of 
antimicrobial factors and endogenous microbiota contributes towards regulating the pH of the FGT to protect 
against genital tract pathogens. Innate immune cells constitutively secrete an array of soluble antimicrobials, 
including secretory leukocyte protease inhibitor (SLPI), human β-defensin 2 (HBD2), lysozyme, lactoferrin, 
Elafin, cathelicidins. Chlamydial infection of columnar epithelial cells and local genital tract immune cells, 
including neutrophils, macrophages, and NK cells, produces soluble antimicrobials chemokines, and pro-
inflammatory cytokines that selectively prevent bacterial infection of target host cells. (e.g., IL-1 released 
from infected epithelial cells promotes Th17 differentiation). Recruitment and activation of adaptive immune 
cells (T and B cells) are also orchestrated by the release of these secreted soluble antimicrobial factors from 
epithelial cells, dendritic cells, and macrophages.  
Humoral: Antibodies potentially can prevent infection by Chlamydia. Immunoglobulin G (IgG) is the 
predominant antibody in the FGT. Antibodies released from plasma cells (IgG and IgA) inactivate 
extracellular chlamydial EB. 
Cell-mediated: CD4+, by IFN-γ production, contributes to host defence by inhibiting intracellular chlamydial 
replication, while CD8+ induces apoptosis of infected cells. 
CTL:CD8+; GM-CSF: granulocyte-macrophages colony-stimulating factor; MMP:  matrix metalloproteinase; GRO-α: growth related 
oncogene-α; TNF: tumor necrosis factor (Hafner et al., 2013). 
http://www.nature.com/mi/journal/v6/n5/full/mi201346a.html. 
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CT Strategies for Evading Host Immune Response 
 
CT pathogenesis depends on the cell population invaded, the initiation of the replicative 
genetic state of the pathogen and the efficiency of the release of effector molecules into the 
host cell. A number of mechanisms can be considered to explain the evasion of host 
immune response. As many other intracellular bacteria (Brinkmann et al., 1987), 
endocystosed Chlamydiae are in fact sequestered within a host derived phagosome during 
the intracellular phase of developmental cycle. Their intracellular location largely protects 
them from antibody and complement attack. Cell mediated immunity is the predominant 
component in controlling CT infection, even if Chlamydia antibodies may play a 
significant role in controlling the infection at a later stage of the disease (Zhong, 2009). 
Moreover, studies using animal models have shown that both the IgA secreting B cells and 
IFN-γ producing CD4+. Th1 T cells are the most important adaptive immunity mechanisms 
in course of infection, although other immune components also play some roles (Malhotra 
et al., 2013). Despite these powerful host defense mechanisms, acute infection (if not 
treated) can activate inflammation, inducing the production of a wide variety of 
inflammatory cytokines, (IL-1, IL-6, IL-8 and TN-α) and can persist in some infected hosts 
(Gottlieb et al, 2010). In fact, Chlamydia species have shown a tendency to cause 
persistent infections that may also play a role in oncogenesis. In this regard, the induced 
inflammatory responses cannot only fail to effectively clear the infection but also 
contribute to inflammatory pathologies (Stephens, 2003). The failure by the host to 
eradicate the disease involves the establishment of a state of chronic infection in which CT 
after internalization into mononuclear cells, enter into a state of quiescence (cryptic body) 
with intermittent periods of replication and characterized by antigenic variation, production 
of Hsps and pro-inflammatory cytokines (capable of evading host defenses) which trigger 
tissue damage (Stratton and Mitchell, 1997). In this regard, Hsp60, an ubiquitous and 
evolutionarily conserved chaperonin, normally sequestered inside the cell, particularly into 
mitochondria, can elicit an immune response in humans which although directed against 
the microbial molecule but also reacts with endogenous Hsp60 (Pockley, 2003). During 
cell stress conditions, as well as during carcinogenesis, this chaperonin becomes exposed 
on the cell surface and/or is secreted from cells into the extracellular space and circulation 
(Figure 10). 
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Fig. 10: Potential effects of anti-CT-Hsp60 antibodies. These antibodies recognize surface-Hsp60 onstressed 
or tumor cells, and consequently, they can lead to either damage and persistence of infection or cell lysis 
producing a regression of certain types of cancer. Immunocomplexes (CT-Hsp60 and anti-CT-Hsp60) can 
cause disease if they form deposits in the renal glomerulus (Mascellino et al., 2011). 
http://www.hindawi.com/journals/isrn/2011/436936/fig3/. 
 
 
Quantification of circulating Hsp60 has recently become a potential useful marker of 
infection for clinicians in patients affected by a variety of diseases. However, interpretation 
of its values should be carefully evaluated, as a correlation between chaperonin levels and 
disease is difficult to establish. Hsp60 is also a ligand of TLR and its expression on cell 
membrane surface’s correlates with apoptotic phenomena (Cappello et al., 2009). During 
CT invasion and intracellular growth, sensors of the host innate immunity (PRR) can detect 
the infection by recognizing microbial components (pathogen associated molecular 
patterns, PAMPs). Chlamydia PAMPs such as Hsp60 and Macrophage Infectivity 
Potentiator lipoprotein (MIP) are recognized by host PRR TLR4 and TLR2 respectively. 
These host receptors selectively recognize a broad spectrum of microbial components and 
endogenous molecules released by injured tissue (Bulut et al., 2002; Bas et al., 2008). In 
human cells, TLR4 recognizes CT LPS and Hsp60 and it is mainly expressed in the tubes 
and endometrium and little in endocervix, while TLR2 recognizes peptidoglycan and it is 
mainly expressed in the tubes and cervix (Mascellino et al., 2011) and appears to be the 
predominant receptor required for an inflammatory response to infection. Interestingly, 
TLR2 and its adaptor MyD88 localize to the periphery of the chlamydial inclusion during 
active infection, suggesting that may signal intracellularly during infection (Bastidas et al., 
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2013). MIP or other lipoproteins could be released from EB surface and RBs, and retain 
inside tissues where they might activate resident cells and perpetuate inflammatory 
response even after the eradication of live bacteria with antibiotic therapy (Bas et al., 
2008). In general, PRRs, upon ligand binding, can lead to activation of various 
inflammatory signaling pathways including NF-kB, NF-IL-6 and MAP kinases. 
TTS apparatus is another mechanism which seems central to the biology of the 
Chlamydiae, as it mediates the translocation of bacterial toxins to the cytosol of infected 
cells. It is present in several important gram-negative bacterial pathogens (Peters et al., 
2007). It consists in a molecular injection system protruding from the outer membrane, that 
appears to be expressed and functional in acute as well as in chronic infection and may 
represent a prominent virulence factor. A major role of T3S may also be involved, ensuring 
growth and development of the pathogen by modifying apoptosis signals or some other 
transcriptional regulation important for Chlamydia survival. 
 
CT Persistence and Chronic Infection 
 
The exact role of persistent stage in the CT developmental cycle as well as the molecular 
mechanisms allowing persistence remains to be elucidated. In vivo studies of 
microorganism persistence are hampered by genotype definition and viability of organism. 
However, characterization of in vitro persistent phase of pathogen and multiple lines of in 
vivo evidence, suggest that CT persists in an altered form during chronic disease (Hogan et 
al., 2004). 
Persistence has long been recognized as a major factor in the pathogenesis of CT disease. It 
has been described as a viable but non-cultivable growth stage resulting in a long-term 
relationship with the infected host cell that may not necessarily manifest as clinically 
recognizable disease. 
It is distinct from unapparent infections, which may or may not involve evident CT growth 
and refers to an atypical, intracellular and metabolically less active state that is difficult to 
resolve not only by the host-defense system, but also by antibiotic therapy. 
Unlike the re-infections believed to be the result of exposure to a CT serotype different 
from the initial, persistent infections are due to the same type of pathogen genotype entered 
into a metabolic quiescent and non-infectious form and responsible of three to ten 
recurrences which can last many years (Dean and Powers, 2001). 
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In vitro studies have shown that several factors including nutrient depletion, cytokines, iron 
restriction, amino acids, Ca++  and certain antibiotics can favor the Chlamydial persistent 
stage (Beatty et al., 1994 ; Raulston ,1997; Dreses- Werringloer et al., 2000). 
IFN-γ is considered a primary host protective cytokine against endocervical CT infections. 
This directly inhibits bacterial growth through the depletion of cellular tryptophan (TRP) 
by indolamine-2,3-dioxygenase (IDO) (Aiyar, 2014), which can stop the expression of late 
proteins, such as MOMP, that in turn stop the progress of RB division and RB conversion 
into EBs leading to aberrant Chlamydial RBs (Sardinia et al., 1988; Beatty et al., 1994). 
A failed or weak Th1 response will allow CT RBs to respond to immune challenge by 
converting into a non-replicating but revivable persistent state (Debattista et al., 2003; 
Leonhardt et al., 2007). CT, in this persistent state, is able to survive and still allows for 
antigen-presentation (Rey-Ladino et al., 2007). A direct consequence of this prolonged 
infection is antibody or Th2-mediated hypersensitivity (Debattista et al., 2003).Moreover, 
an over-stimulated Th1 response will lead to delayed-type hypersensitivity and an 
increased risk of IFN-γ-mediated tissue damage, that is likely a consequence of an initially 
dominant Th2 response. Infected cells increase through new infections and decrease by cell 
death and clearance by host immune responses; nevertheless, antibiotic treatment, reduces 
the number of infected cells by eradicating CT; depletion of infected cells further, removes 
the antigen that is reflected on the immune system. As a direct result, the arrested 
immunity hypothesis underscores the importance of gaining a better understanding of the 
interplay between the immune biology of infection and the use of antibiotics (Gottlieb et 
al., 2010). This hypothesis suggests that early antibiotic treatment effectively attenuates the 
optimal development of protective immunity, leaving individuals as susceptible as before 
to reinfection with the same or a new serovar. Therefore the treatment may attenuate 
protective immunity in some persons and conversely that natural immunity may protect 
against reinfection (Marrazzo and Suchland, 2014).  
In this context, a complete transcriptome analysis of CT serovar D growth in HeLa cells 
exposed to IFN-γ, demonstrated the up-regulation of many genes involved in active 
metabolic processes in the aberrant RBs, including those involved in DNA repair and 
recombination, protein translation, and phospholipid utilization (Belland et al. 2003). 
Moreover, separate studies at transcriptional level have demonstrated a down-regulation of 
CT MOMP in HeLa cells and an up-regulation of CP MOMP in response to IFN-γ 
stimulation (Mathews et al. 2001; Molestina et al. 2002). This underlines the different roles 
played by MOMP in the two species. Also, Hsp60–1/groEL was found to be expressed 
predominantly during acute phase growth of CT serovar K and that the Hsp60-copy2/Ct-
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604 gene transcript/protein was increased in iron-induced persistent cultures (Gérard et al. 
2004). 
Antibiotics such as penicillin and quinolones (such as ciprofloxacin and ofloxacin) have 
shown to favor persistence instead of resolving infection because of inducing aberrant but 
viable particles which may explain therapy failure (Dreses-Werringloer et al. 2000). CT 
exposure to penicillin leads to enlarged and aberrant RBs, the so called “penicillin forms” 
that return to normal growth after penicillin removal. On the other hand, although 
Chlamydial RBs are killed by macrolide treatment (azithromycin), residual antigens can 
persist for more than 28 days continuing to harbour inflammatory responses (Wyrick and 
Knight 2004). 
In vivo studies have shown that the presence of Chlamydial antigens and nucleic acids even 
in absence of cultivable organisms is indicative of persisting organisms probably as result 
of immunologic stimulation during chronic disease. Chlamydia rRNA demonstration may 
provide evidence for in-apparent Chlamydial infections (Beagley et al., 2009). 
All different species of Chlamydia have tendency to cause persistent infections that may 
play a role in chronic diseases (inflammation and scarring with significant damage to the 
host) and oncogenesis. 
Previous studies have also revealed that in CT infection, the cytosolic levels of Hsp60 in 
vivo gradually increase during carcinogenetic steps, from normal tissue to dysplasia to 
fully developed carcinoma in various organs (Cappello et al., 2009). 
 
CT and Apoptosis 
 
Cell death by apoptosis is an active and important defense mechanism against invading 
pathogens. Apoptosis has a direct role in many infectious diseases, especially those caused 
by viruses, intracellular protozoans and intracellular bacteria (Byrne and Ojcius, 2004). For 
many of these pathogens, the apoptotic signaling starts from the pathogen and not by the 
host cell. In this regard, Chlamydia inhibits apoptotic signalling cascades during 
productive growth as part of its intracellular survival strategy (Miyairi and Byrne, 2006) in 
order to maintain the integrity of the host cell for the completion of its intracellular growth 
(Zhong, 2009). This is in part due to the proteolysis of host proteins for ensuring its own 
intracellular replication while maintaining the integrity of the infected host cells for long 
periods of time. CT also inhibits apoptosis during persistent growth or in phagocytes, but 
induces apoptosis in T cells, which suggests that apoptosis has an immunomodulatory role 
in Chlamydial infections. The anti-apoptotic activity has shown to be prolonged during CT 
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persistence. This strengthens the hypothesis that active CT metabolism maintains host cell 
integrity and contributes to intracellular survival (Bastidas et al., 2013). 
The circumstances that dictate whether the Chlamydiae inhibit or activate host cell death 
reflect important pathogenic considerations, including whether if an acute or chronic 
infection is in progress and whether intracellular Chlamydia growth is programmed to go 
through a productive infectious cycle or is stalled under non-productive growth conditions. 
It is possible that apoptotic activity is controlled to some extent by the intracellular growth 
status of the Chlamydiae, which can be influenced by any or all of these considerations 
(Byrne and Ojcius 2004) and by strain. While for CP, active inhibition of apoptosis occurs 
in epithelial cells, macrophages and neutrophils, for CT and C. psittaci, the anti-apoptotic 
activity has been demonstrated mainly in epithelial cells later in their developmental cycle 
(Miyairi and Byrne, 2006; van Zandbergen et al., 2004 ). It is not known exactly how pro-
apoptotic and antiapoptotic effects correlate with the wide spectrum of clinical 
manifestations and Chlamydial diseases. A Chlamydia induced apoptotic activity has been 
hypothesized during acute manifestation of disease, whereas inhibition of apoptosis, in 
chronic disease states (Byrne and Ojcius 2004). Chronic infection and clinical persistence 
are closely related. Inhibition of apoptosis could represent a mechanism that has evolved to 
establish a chronic infection. Several lines of evidence suggest that to provoke chronic 
infection, CT could adopt several strategies. One of these consists of being silent, resulting 
in asymptomatic infections that cannot be diagnosed at that time. This promotes bacterial 
progression, even to the most internal tissues. In addition, CT MOMP displays variable 
immunodominant antigenic epitopes. Variations in these epitopes explain the absence of 
strain specific immunity and multiple re-infections by different serovars or by the same 
mutated serovar are still possible (Millman et al. 2001). For these reasons, even if the 
initial infection is resolved, re-infections are possible and can lead to auto-pathological 
immune response induction (Beatty et al.1994). Although re-infections occur, the 
refinement of Chlamydial diagnostic methods will allow us to establish whether CT can 
persist. 
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Interaction between CT and HPV 
 
Infectious agents play an important role in the aetiology of certain human malignancies, 
and are thought to be responsible for around 20% of the worldwide cancer burden (Parkin, 
2001). Much of the burden of cancer incidence, morbidity, and mortality occurs in the 
developing world (up to 27%), with a large body of evidence regarding the role of viruses 
such as human papilloma virus (HPV), hepatitis B virus (HBV) and Epstein-Barr virus 
(EBV) in the complex processes of carcinogenesis of the cervix, stomach and liver (Jemal 
et al., 2010). In addition to viral agents implicated in carcinogenesis, a theory of possible 
association between bacterial infection and cancer has been proposed in early nineteenth 
century (Lax, 2005). Moreover, many bacteria that cause persistent infections produce 
toxins that disrupt cellular signaling, alter the regulation of cell growth, induce 
inflammation or directly damage DNA. Toxins may also mimic carcinogens and tumor 
promoters and might represent a paradigm for bacterially induced carcinogenesis. The 
question however remains quite controversial especially with regard to certain species of 
bacteria for oncogenic properties. 
Some authors have suggested that exposure to CT-Hsp60 may be a risk factor for 
development of cancer (Di Felice et al., 2005), while the development of anti-CT-Hsp60 is 
also proposed to protect against malignancy (Cappello et al., 2009). Chronic persistent 
infection with CT to the upper genital tract is able to incur significant damage to the 
reproductive tract and proposed to induce ovarian cancer (Quirk & Kupinski, 2001). 
Although epidemiological data have not yet provided consistent evidence about a real 
implication of CT in cervical cancer, the co-infection with Human papillomavirus (HPV), 
sharing the transmission route and the same risk factors, have been recently highlighted 
(Simonetti et al., 2009; Vaccarella et al.,2010; Paavonen, 2012). A role for CT as cofactor 
was suggested, since it seems to facilitate the penetration of HPV and the progress of 
cervical lesions interfering in the immunological response (Deluca et al., 2011). Moreover, 
some authors recently detected a high-risk for the development of cervical cancer in 
patients with HPV infection and history of CT (Jensen et al., 2014). Nevertheless, the 
prevalence and distribution of HPV genotypes associated to CT infection and its clinical 
persistence are poorly explored. On this basis, the characterization of HPV infection in 
women suffering from CT could be important in generating hypotheses regarding the 
possible synergism of these pathogens in cervical malignancy (Bathla et al., 2013; Silva et 
al., 2014; Tavares et al., 2014; Shew et al., 2013). Recently, a case-control study showed 
that CT is not able to modify the risk of progression to a high-grade lesion of HPV-positive 
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women but can increase the susceptibility of the cervical epithelium to further HPV 
infection and its persistence (Safaeian et al., 2010) Specifically young age (less than 25y) 
is related to an increased risk of both HPV and CT infection (Silva et al., 2013). 
Furthermore, the role of CT chronic infection in promoting HPV susceptibility has been 
evaluated. In some cases this infection has been associated with cervical atypia and/or 
metaplasia, which in turn, may increase the risk of neoplasia (Luostarinen et al., 2013). 
In this setting, to investigate a pathogen as CT potentially implicated as oncogenic for its 
tendency to cause chronic and persistent infections, together with HPV co-infection, could 
have a great importance for the public health. 
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OBJECTIVES OF THE STUDY 
 
As described previously, HPV and CT are STIs with significant implications for global 
health. In a large series (2009-2014) of women from the North-Eastern Italian area, we 
aimed to: 
• highlight, by molecular techniques, the overall prevalence of HPV and CT 
infections in cervical swabs (CS) specimen of women that perform these types of 
investigations. 
• highlight the overall prevalence of CT/HPV co-infections. 
• highlight the prevalence of CT chronic infections and its performance in the context 
of HPV co-infections 
• evaluate the distribution of HPV genotypes in CT/HPV co-infections, compared to 
women infected with HPV only 
• examine the prevalence of single or multiple HPV infections in the setting of 
CT/HPV co-infections compared to women infected with HPV only. 
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MATERIALS AND METHODS 
 
Clinical Specimens 
 
A retrospective study was conducted on a large cohort of 7135 consecutive cytology 
samples collected starting January 2009 to December 2014 during gynecological health 
checks from immunocompetent women in Trieste, Italy.  
Of this series, 6214 cervical swabs (CS) were collected from women at risk for C. 
trachomatis infection of which 5481 from Outpatients (mean age 35 ± 10y) asymptomatic 
women, 733 were from symptomatic women attending Sexually Transmitted Infection 
(STI) clinic (mean age 33 ± 10y) while 921 (mean age 43 ± 10y) samples were from 
women at risk for HPV infection attending as outpatients a second level centre for Cervical 
Cancer prevention.  
CS were collected using a 200 mm polyethylene Cervex brush device (Rovers Medical 
Devices B.V., The Netherlands) and suspended in 1.5 ml of TE buffer. The top portion 
uses a soft, flexible brush to obtain cell samples, while the shape allows the top edges to 
follow the contours of the cervix. The longer middle bristles reach deep into the 
endocervical canal while the shorter bristles touch both the ectocervical area (external os) 
and the transformation zone (T-zone). The sample was divided into 3 aliquots of 500 µl 
each and stored at -80°C until analysis.  
No informed consent or any action of the patient was required for this study because the 
anonymity of the patients was guaranteed. The analysis on this series of samples was 
conducted blinded. 
 
Isolation of DNA from cervical cells 
 
DNA isolation was performed within 24 hours after the collection of the samples. After 
specimen centrifugation, 500 µl of each sample was extracted using the NucliSENS® 
EasyMAG® automated system for total nucleic acid extraction (Biomérieux S.p.a. 
Florence, Italy), according to the manufacturer’s instructions.  
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HPV detection and characterization 
 
HPV was detected in CS samples by the bead-based Luminex suspension array technology 
(Luminex Corporation, Austin, TX). HPV genotyping was performed using the type 
specific E7 polymerase chain reaction bead-based multiplex assay (TS-E7-MPG, IARC, 
Lyon, France) able to identify 27 HPV types ( HR-HPV types HPV16-18-31-33-35-39-45-
51-52-56-58-59-66-68-73-cp108, pHR-HPV types HPV26-53-67-69-82 and LR-HPV 
types HPV6-11-55, -81, -83, -84 and the β-globin gene as internal positive control. Viral 
genomes detected by this assay ranged from 10 to 1,000 copies (Comar et al, 2012; 
Bellaminutti et al., 2014). Briefly, HPV genotypes were detected as the median 
fluorescence intensity (MFI) of at least 100 beads per bead set. The background value for 
each probe was considered the MFI value, resulted from hybridization mixture without the 
addition PCR product. The cut-off was computed by adding 5 MFI to 1.1 the median 
background value.  
An additional set of HPV types including LR-HPV40,-42-43-44-54-61-70 was identified 
by the Anyplex™ II HPV Detection assay (Seegene Inc., Arrow diagnostics, Italy) using 
the CFX96 ™ Real-time PCR System (Bio-rad, France) as indicated by the supplier. This 
assay is based on a new developed TOCE™ technology, that can perform multiplex 
examination by either End point-CMTA (end point-Catcher Melting Temperature 
Analysis) or Cyclic-CMTA (Cyclic-Catcher Melting Temperature Analysis) method. 
Cyclic-CMTA method can discriminate major pathogens in the co-infected samples. It is a 
multiplex Rt-PCR assay that permits the simultaneous amplification, detection and 
differentiation of target DNA of 19 HR-HPV types and 9 LR-HPV types. A human 
housekeeping gene was utilized as an endogenous internal control ensuring DNA 
purification, PCR reaction and specimen quality . 
 
CT detection  
 
Real Time PCR (RT-PCR) for CT DNA detection was performed with a commercial kit 
(CTDNA, Dia.Pro, Italia) using the ABI Prism 7900 Sequence Detection system (Applied 
Biosystems, Italy) following manufacturer’s protocol. The reproducibility detection limit 
of the assay was 5 copy/µl.  
  
37 
 
 
CT HSp60 Real Time PCR detection 
 
Total RNA was extracted using 500 µl of a stored aliquot, by RNeasy Mini kit (Qiagen 
GmbH, Hilden, Germany). In order to avoid DNA genomic contaminations, RNA final 
concentration (25 µg/ml) was treated with Dnase I (RNase-Free DNase Set, Qiagen 
GmbH, Hilden, Germany) and eluted in 50 µl of distilled water. cDNA was synthesized 
using the SuperScript VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA).  
A quantitative Real Time PCR (qPCR) was performed for the quantification of the 
transcription level of Hsp60 gene (Ct604) as previously described (Contini et al., 2012;  
Seraceni et al., 2014). Briefly, PCR reaction, in a final volume of 20 µl, contained: 5 µl of 
cDNA, 2 µl LC FastStart DNA Master SYBR Green I (Roche Molecular Biochemicals, 
Germany), 5 mM MgCl2 and 0.8 µM each primer. The thermocycling condition was: 95 °C 
at 10 min followed by 40 cycles of 15 s at 95 °C and 1 min at 63 °C. To avoid false 
positive results a serial standard curve, a negative control with PCR-grade water and a 
positive control (CT strain-TW-3) were included in the assay.  
The concentration of unknown clinical samples based on their Ct values was determined 
with analytical software (Software SDS 2.4; Applied Biosystems) (Brankatschk et al., 
2012) while the specificity of the reaction was further confirmed by agarose gel 
electrophoresis analysis, which showed the expected amplification product of 161 bp in 
length.  
The sensitivity of each run was determined to be the lowest dilution of DNA (2 10-4 ng/ml 
corresponding to one genome copies/µl) that can be detected to 7900HT instrument 
(Applied Biosystems, Italy). The standard curve equations were used to calculate the 
absolute copy number of gene mRNA. Results were expressed as mRNA CT genome 
copies/µl found inside each clinical sample. 
 
CT genotyping  
 
OmpA gene was employed for CT genotyping; positive amplicons were purified, 
sequenced and analyzed with BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) as 
previously described (Contini et al., 2013). 
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Statistical Analysis  
 
All statistical analyses were performed using the IBM SPSS Statistics 20 statistical 
program. Chi Square Test was used to compare frequencies of discrete variables. Fisher 
Exact Test was applied when necessary. P value ≤ 0.05 was considered as the threshold of 
statistical significance for all tests.  
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RESULTS 
 
HPV infection 
 
Table 1 described the characteristic of HPV infection stratified according to age (clinical 
recommended cut-off 25 years). The age, usually referred to a cut-off of 25y, represented 
the most important predictor factor for CT infection (Eggleston et al., 2011) and was 
included as a criterium in the prevention guidelines by the Centre for Disease Control and 
Prevention (Workowski and Berman, 2011). Health authorities in some European and 
other high income countries recommend screening in this age group to allow both early 
treatment of asymptomatic infection and the prevention of long term complications 
(National Chlamydia Screening Programme Standards, 2012) and half an HPV infections, 
who represent only 25% of the sexually experienced population, occur in young people 
(15-24y) (CDC, 2014). 
In both groups the prevalence of HPV tested at 39% (59/153 ≤25y and 300/768 in > 25y).  
Among HPV infections, the 60% (216/921) was represented as single HPV genotype: 53% 
(31/59) in women ≤ 25y and 62% (185/300) in women > 25y. Multiple genotypes were 
detected in 40% (143/921) of the samples: 47% (28/153) in women aged ≤ 25y and 38% 
(115/300) in women > 25y. These data showed a high frequency of multiple infections in a 
cohort of younger women with a trend of prevalence similar to that recovered for single 
infection. All these women tested negative for co-infection with CT. 
 
CT infection  
 
In this series, the overall prevalence of CT infection was tested at 4%. A statistically 
significant high frequency of infection was found in women with ≤ 25 y, tested at 14% 
(127/885) (p < 0.0001), of specimens while in women > 25y, CT was detected in 2% 
(124/5329). 
CT chronic infection, determined through the quantification of Hsp60 expression, showed 
a prevalence of 57% (144/251) with a higher frequency in younger women which was 
found in 69% (88/127) (Table 2). 
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CT and HPV co-infection and HPV genotypes distribution 
 
CT/HPV co-infection was present in 58% (145/251) of samples resulted positive for CT. 
The distribution of co-infection was of 68% (86/127) in women with less than 25y and of 
48% (59/124) in women over 25y. HPV was present as single or multiple genotypes in 
32% and in 68% of the overall samples, respectively. Interesting, HPV multiple infections, 
according to age, were highly expressed in both cohorts, when compared to older women 
(Table 2). Figure 11, describes the overall view of the genotypes distribution in women 
with CT/HPV co-infection compared to women positive for HPV. 
In CT/HPV co-infected women, the distribution of HPV as single and multiple genotypes 
accounted for 32% and of 68%, respectively, as for women exclusively infected by HPV 
only.  
The overall genotypes distribution of HPV in women diagnosed with CT/HPV compared 
to women with single HPV infection is described in Figure 12. A large number of HPV 
genotypes including high, intermediate and low risk genotypes, has been detected at high 
frequency: HPV31 (28%), HPV42 (23%), HPV66 (18%), HPV51 (16%), HPV6,-56,-73 
(15%) and HPV16 (14%). Of interest, the LR type, HPV44 (12%) was detected in this 
group of women only. Conversely, in women showing HPV only, the HR-HPV16 
represented the one most frequently detected genotype (33%) followed by HPV31 (16%) 
and HPV62 (12%). Interesting, HPV55,-61,-62,-81,-82,-83,-84,-cp108 were exclusively 
detected in these women. 
 
HPV genotypes distribution in single and multiple infections from CT/HPV and HPV 
women. 
 
The distribution of HPV genotypes in single and multiple infections independently of the 
presence of CT is resumed in Figure 13. A different distribution pattern was particularly 
found in CT/HPV co-infected women where each genotype was detected with higher 
prevalence in multiple infections. HPV31 (23%), HPV 42 (19%), HPV56,-66 (15%), 
HPV6,-51 (14%), HPV73 (13%), HPV16,-59 (12%) were the main genotypes identified. In 
addition, HPV 31 (5%), HPV42 (4%), HPV39,-66 (3%) were the most prevalent genotypes 
detected as single infection in CT/HPV co-infected women.  
In CT/HPV multiple infection, the association between specific HPV genotypes was 
highlighted. In fact HPV6,-51,-59,-66 were detected together in 19% of the samples while 
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HPV31-56 and HPV51-66 in 8% in 6%, respectively. Moreover, a high percentage of LR-
HPV genotypes generally not detected in this area, has been recovered exclusively in 
CT/HPV multiple co-infection.  
Of note, HPV16 was the most representative genotype (21%) in women with a single 
infection while in those with multiple HPV infections, the prevalence of HPV61-62, was 
higher (8% and 10%) with respect to the single infection (2%). HR-HPV52 (6%) was 
presented exclusively in this group. 
 
CT Hsp60 chronic infection and HPV infections 
 
CT chronic infection was diagnosed in 57% (144/251) of women. The mRNA expression 
of CT-Hsp60 gene was positively associated with HPV co-infection, with an overall 
frequency of 68% (98/144). Specifically, age distribution analysis showed that in young 
women the 72% (63/88) of CT/HPV co-infection was due to a chronic status (Table 3). 
Regarding, HPV genotypes distribution, HPV single infection was represented in 31% 
(30/98) in contrast with multiple infection which accounted for 69% (68/98) of women. In 
particular, 78% (49/63) (p < 0.0221) of younger women presented multiple infections 
compared to 54% (19/35) of older women. On the contrary, in older women the prevalence 
of HPV single infection were higher 46% (16/35) than in younger women, 22% (14/63). 
The level of CT-Hsp60 expression was confirmed, significantly lower (± 805 copy/µl) in 
CT/HPV co-infected women compared to women with only CT infection (± 1993 copy/µl). 
CT serotyping confirmed the trend obtained in our previous study, with high frequency of 
F serotype. 
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Table 1: Total prevalence of HPV infection in women (2009-2014) according to age cohorts (clinical cut-off 
25 years of age). 
 
Age 
Samples 
n. (%) 
 
HPV- 
 
HPV+ 
 
Genotypes 
 
   Single Multiple 
 
≤ 25 
153 (17) 
 
 
94 (61) 
 
59 (39) 
 
31 (53) 
 
28 (47) 
>25 
768 (83) 
 
468 (61) 300 (39) 185 (62) 115 (38) 
921 564 (61) 359 (39) 216 (60) 143 (40) 
     
 
 
Table 2: Total prevalence of CT infection in women (2009-2014) according to age cohorts (clinical cut-off 
25 years of age). 
 
Age 
Samples 
n. (%) 
 
CT- 
 
CT+ 
 
CT+/HPV+ 
 
Genotypes 
 
 
Single           Multiple 
 
HSP60+ 
 
≤ 25 
885 (14) 
 
758 (86) 
 
127 (14) 
 
86 (68) 
 
20 (23) 
 
66 (77) 
 
88 (69) 
 
>25 
5329 (86) 
 
 
5205 (98) 
 
124 (2) 
 
59 (48) 
 
27 (46) 
 
32 (54) 
 
56 (45) 
6214 5963 (96) 251 (4) 145 (58) 47 (32) 98 (68) 144 (57) 
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DISCUSSION 
 
In our previous pilot study conducted on CS from 1071 women, a high prevalence of CT/ 
HPV co-infection was documented in 60.4% of tested samples. Of interest, the 62.5% of 
co-infection included multiple HPV genotypes and was associated to a CT chronic status. 
(p < 0.001) (Seraceni et al., 2014). 
In order to corroborate this result, we performed a large retrospective study on 7135 CS 
samples from females (range age from 14y to 85y) with particular attention to the 
association between CT positivity and the characteristic of HPV co-infection, including 
genotypes distribution in single and in multiple infection.  
In the present study, HPV was present in 39% (359/921) of women (mean age 39y) with 
clinical indication for HPV infection, while CT infection was detected in 4% (251/6214) of 
women (mean age 29y) considered a risk for CT.  
The CT chronic status, through Hsp60 expression, was documented in 57% (144/251) of 
CT positive women (mean age 26y). The CT/HPV co-infection tested at 58% (145/251) 
(mean age 28y) of which 68% was chronic infection. 
As previously described, the age represents an important predictor factor in STIs infection. 
European survey, in asymptomatic women, reported a prevalence of CT infection ranging 
between 1.7% and 17% depending on social–economical context (Paavonen, 2012), while 
in a new systematic meta-analysis from 11 EU/EEA Member States, one non-EU/EEA 
European countries and four other high income countries, chlamydia prevalence resulted 
low in ≤ 26y people sexually active and very heterogeneous, compared to women ≤ 25y, 
ranging from 0.6-10.7% in (Redmond et al., 2015).  
In the last report (2009-2012) from Italian Institute of Health, the overall CT prevalence 
resulted of more 3.2% than women (2.3%) (Salfa et al., 2014), placing Italy among the 
countries with a low endemicity for this infection (Marcone et al, 2012).  
In contrast with the national data, in our series, the prevalence of CT infection confirmed 
to be at 4%, with the highest rate of infection (14%) in young women (≤25y) confirming 
age as an important risk factor. In addition, our large study showed a high prevalence of 
CT/HPV co-infection (58%) mostly in younger women (68%).  
On the contrary, recent investigation in young women (16-26y) from different Italian areas 
reported a CT prevalence of 5.8% and a CT/HPV co-infection of 2.7% (Panatto et al., 
2015). The above discordancy, compared to our data could be due to the molecular assay 
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typology used to test both CT and HPV, or to the different geographic areas (3 cities in 
northern Italy) or to the specific young women cohort examined (16-26y).  
 
Of note, CT infection was associated to HPV multiple genotypes in 78% of the analyzed 
cases suggesting a strong susceptibility of these women in acquiring multiple HPV 
infections or, as recently demonstrated, a role of CT in type-specific HPV re-detection due 
to reactivation of a low level of persistent oncogenic HPV (Shew, 2013).  
Several epidemiological data suggested that CT may play a role in cervical carcinogenesis 
(Sillins et al., 2005) although the question of how CT synergize with HPV in this 
transforming process is still debated (Idahl et al., 2010). CT/HPV co-presence was found in 
cervical precancerous lesions, and in HPV positive patients were recovered IgG antibodies 
or CT DNA (Paavonen, 2012; Silva et al., 2014; Tavares at al., 2014).  
Regarding the characteristic of HPV infection among infected women, the presence of 
single or multiple infections showed an interesting distribution. HPV single infection was 
highly detected (60%) in women infected solely with HPV, while, in CT/HPV co-infected 
women, multiple infections were found prevalent (68%). Moreover, HPV genotypes 
distribution resulted extremely different. These findings seem to reinforce previous 
published data (Carozzi et al., 2014) which suggest that the HPV genotypes variability 
seems to depend on the local dynamics of transmission and local type mix, a phenomenon 
also reported in different Italian geographic area (Agarossi et al., 2009; Giorgi Rossi et al., 
2010, Giuffrè et al., 2010; Bellaminutti et al. 2014). 
In a worldwide meta-analysis on prevalence of HPV in women with normal cytology, 
although it was high and variable across world regions, HR-HPV16 (22.5%) followed by 
HR-HPV18,-52-,31-58,-39,-51,-56 and LR-HPV6, were the most common genotypes 
detected (Bruni et al., 2010). In Italy, various authors detected HPV16 (Giorgi et al., 2011; 
Bianchi et al., 2013; Carozzi et al., 2014) or HPV belonging to groups 1, 2A or 2B, among 
subject with CT/HPV co-infection, (Panatto et al., 2015) as the most prevalent types. 
Interestingly, in our study, HPV16 resulted the most representative genotype in women 
infected by HPV only (overall 33%, 21% in single HPV infection), followed by HPV31 
(17%). Moreover, some viral genotypes were recognized as the most representative 
genotypes exclusively in this group of women showing HPV61,-62 and HPV52. 
While HPV61 and 62 were detected in Italy below 5% (Giuffrè et al., 2010), HPV52 seems 
one of the most common genotypes detected in Korea and Asian patients associated to 
invasive cancer and HSIL (Cho et al., 2015, Wang et al, 2015), whereas in Italy its 
prevalence was heterogenic between various centers (1.9-7.1%) (Carozzi et al., 2014).  
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Sammarco et al., 2013, found that almost half of women with HR-HPV present a persistent 
HPV31,-39,-73 infection, whereas the most frequently detected HPV genotypes were 
HPV16,-31 (common at the follow-up) and HPV52,-53. The authors in these women 
detected a low presence of CT and Mycoplasma spp infection, in agreement with our 
results whilst, in women infected with HPV, CT was not present, thus reinforcing our 
hypothesis that a primary HPV infection could reduce subsequent CT penetration and 
consequently the infection. Tavares at al., 2014, based on their collected data, have 
suggested that CT infection may play an important role in the natural history of HPV, thus 
suggesting  that the HPV and CT association seems more related with potentiating mutual 
than with common way of transmission. Moreover, studies in vitro on CT immunological 
response have demonstrated that INF-γ can inhibit CT development (Shemer and Sarov, 
1985; Wyrick, 2010), while in HPV infection, INF-γ increases its expression (Scott et al., 
1999). In a recent study (Colín-Ferreyra et al., 2015) a high expression level of INF-γ was 
demonstrated in women co-infected with CT/HPV, promoting the CC development.  
The association between CT and HPV genotypes at high risk of cancer development has 
been previously described. Panatto et al., 2015, by examining a regression analysis, found 
in co-infected women with CT a significantly higher odds of infection of single HR-HPV 
or combinations of multiple HPV genotypes with at least one HR-HPV type. This finding 
is of particular importance for the primary prevention of CC, since concurrent CT infection 
has been found to be associated with the persistence of HR and multiple HPV genotypes in 
female adolescents (Samoff et al., 2005). In turn, the persistence of HR-HPV genotypes 
among cytologically normal women leads to a greatly increased risk of CC (Chen et al., 
2011). By contrast, the HPV pattern distribution that we observed in our study in CT/HPV 
co-infected women, demonstrated a high frequency of HPV genotypes usually lower, 
compared to HPV Italian screening (Giorgi et al., 2011; Carozzi et al., 2014). Among 
these, HPV31 and HPV42 were detected both in multiple (23%, 19%) and in single 
infections (5%, 4%) respectively. In CT/HPV co-infected women, the association between 
specific HPV genotypes was emphasized. HPV6,-51,-59,-66 were detected together in 19% 
of the samples, HPV31-56 in 8% and HPV51-66 in 6%.  
In Italy, HPV56 was identified between the most frequent genotypes (Carozzi et al., 2014), 
associated to multiple infection together also to HSP51 (Agarossi et al. 2009), that in North 
Sardinia, which was unusually found high in invasive cervical neoplasia (Piana et al., 
2013). Moreover, we recovered a high percentage of LR-HPV genotypes (HPV40,-42,-43,-
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44) exclusively in CT/HPV multiple co-infections, which were not generally detected in 
this specific area. 
An interesting finding of our study was the analysis of the presence of CT chronic 
infection. The CT-Hsp60 gene expression, linked to CT chronic status, was found 
positively associated with HPV co-infection in 68% of women and particularly in 72% of 
young women, confirming our previously data. Of note, 78% of younger women presented 
multiple infections compared to 54% of older women. On the contrary, in older women, 
the prevalence of HPV single infection was higher than that recovered in younger women 
(46% vs 22%). Moreover, the expression of Hsp60 gene has been found significantly lower 
in HPV co-infected women compared to women infected with CT only. 
A discussion of this finding can be merely speculative, suggesting that the maintenance of 
a steady-state level of transcription of Hsp60 gene could favor a balance between the 
Hsp60 induced pro-inflammatory microenvironment and HPV coexistence (Silva et al., 
2014). The chronic inflammation caused by CT increases oxidative stress proteins that 
seem to trigger HPV cell entrance and replication or enhance DNA breaks that may 
promote viral integration (Deluca et al., 2011; Silva et al., 2014; Tavares at al., 2014). 
Although it has been suggested that the concomitant presence of HPV viral oncoproteins 
during Hsp60 expression may lead to the ability to survive apoptotic stimuli, uncontrolled 
proliferation and, finally neoplastic transformation, in this study, specific HPV multiple 
genotypes were found associated to CT chronic status, independently of the risk attributed 
to each genotypes (Dean et al., 2008; Cappello et al., 2009). 
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CONCLUSIONS 
 
The results of this large study confirmed that a high prevalence of multiple HPV infections 
has been associated with CT chronic infection in young women without cervical lesions. 
Of remarkable interest, specific HPV genotypes seem to be more frequently associated to 
CT co-infection. These data may deserve further consideration, owing to the accumulated 
evidence that the chlamydial chronic status could contribute to favor specific HPV 
genotypes representing possible implications for the prevention of cervical cancer. 
Moreover, CT/HPV co-infection associated to young age support the possibility that CT 
could increase the risk for pre-cancer lesions in asymptomatic young women, in line with 
the active role of CT in favoring cells chromosome instability and cervical precancer 
(Grieshaber et al., 2006; Knowlton et al., 2011).  
Even if CT is not present in cervical adenocarcinomas (Quint et al., 2009), its ability to 
cause a local inflammatory process in the upper genital tract facilitates HR-HPV cell 
transformation during carcinogenesis. It is worth nothing that CT/HPV co-infection, due to 
the same modality of transmission, is increasing in sexually active young women and 
therefore early diagnosis and treatment of infected individuals is required to prevent the 
spread of the disease and severe sequelae (Verteramo et al., 2009).  
Collectively taken, data from this study emphasized the need of a screening program for 
CT in young women that could be associated to HPV. HPV testing can thus identify 
women at risk of cervical cancer, reducing cervical cancer incidence in a cost-effective 
manner in the developed world. HR-HPV types infection has been found in all cervical 
carcinomas and the persistent infection with the same genotype, strongly increases the risk 
of developing high-grade pre invasive disease. Although HPV infection is spread among 
young populations worldwide, the cervical cancer screening program in Italy, covered 
from Public Health System, is addressed to women over the age of 25 only, independently 
from their clinical history and the age of the first intercourse, in contrast with other 
European nations and the USA.  
In conclusion this study adds new findings regarding the epidemiology of HPV and CT 
distribution in young asymptomatic women from North-Eastern Italian area and highlights 
both the high frequency of CT and CT/HPV co-infection detection in comparison to the 
National data. The high risk associated with concomitant CT and multiple HR-HPV 
infections in young women suggests that early prophylactic HPV vaccination and a 
screening program for CT/HPV co-infection could play a significant role in cervical cancer 
prevention.  
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Chlamydia trachomatis causing chronic inflam-
matory diseases has investigated as possible
human papillomavirus (HPV) cofactor in cervi-
cal cancer. The aim of this study is to evaluate
the prevalence of Chlamydia trachomatis and
HPV co-infection in different cohorts of asymp-
tomatic women from a Northern Italy area at
high incidence for cervical cancer. Cervical
samples from 441 females were collected from
Cervical Cancer Screening Program, Sexually
Transmitted Infectious and Assisted Reproduc-
tive Technology centres. HPV and Chlamydia
trachomatis were detected simultaneously and
genotyped using a highly sensitive bead based
assay. The overall prevalence of Chlamydia
trachomatis was estimated 9.7%, in contrast
with the reported national data of 2.3%, and
co-infection with HPV was diagnosed in the
17% of the samples. In females  25 years of
age, the infection reached a peak of 22% and
co-infection with HPV of 45.8% (P< 0.001). Of
note, in young females diagnosed with low
grade cervical lesions, no significant difference
between Chlamydia trachomatis and HPV dis-
tribution was observed, while differently, HPV
co-infection was found significantly associated
to the presence of intraepithelial lesions when
compared to older females (20% vs. 1%;
P< 0.001). In this study, the use of a high
sensitive molecular technique exhibited higher
analytical sensitivity than the referred assays
for the diagnosis of Chlamydia trachomatis
and HPV co-infection in asymptomatic females,
leading to reduction of the potential to identify
incorrectly the infection status. An active
screening for timely treatment of Chlamydia
trachomatis infection is suggested in young
females to evaluate a possible decrease in
incidence of pre-cancer intraepithelial lesions.
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INTRODUCTION
Human Papillomavirus (HPV) and Chlamydia tra-
chomatis are considered among the most common
sexually transmitted infections worldwide [Bosch
et al., 2012; Forman et al., 2012; Ferna´ndez-Benı´tez
et al., 2013; Gottlieb et al., 2013].
A persistent infection with an oncogenic high risk-
HPV type is recognized as a crucial event for cervical
cancer development [Bosch et al., 2008]. Although
only a small number of females infected with HPV
develop cervical cancer, cervical precursor lesions
designed as squamous intraepithelial lesions are
frequently diagnosed, a process influenced highly by
the HPV genotype and by other factors.
There is a great body of evidence showing that
suboptimal host immune response could explain the
inter-individual differences in the outcome of HPV
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infection. Most of HPV infections acquired during
sexually active life are resolved, specifically in young
female, after a median follow-up of 6 months whereas
changes in the immunological response due to addi-
tional antigenic stimuli, such as a concurrent infec-
tion, may decrease the host ability to resolve HPV
[Mu~noz et al., 1996; Braaten and Laufer, 2008].
Microorganisms causing chronic inflammatory dis-
eases, such as Chlamydia trachomatis, have been
investigated in the last decade as associated possible
risk factor for HPV transmission and persistence
cooperating in the cervical carcinogenesis process
[Samoff et al., 2005; Silins et al., 2005; Luostarinen
et al., 2013; Shew et al., 2013].
Chlamydia trachomatis is a potent immunogen
that highly stimulates the chronic inflammation
pathway leading to a rapid immune response on the
part of lymphocytes activated previously [Choroszy-
Kro!l et al., 2012]. The clinical course is usually
subacute although, due to the high frequency of the
asymptomatic phase, Chlamydia trachomatis may
induce host chronic inflammation, epithelial tissue
damage and pelvic inflammatory disease. In some
cases, the infection has been associated with cervical
atypia and/or metaplasia, which in turn, may in-
crease the risk of neoplasia [Luostarinen et al., 2013].
European population-based studies reported that the
prevalence of Chlamydia trachomatis in asymptomat-
ic females ranges between 1.7% and 17% depending
on social–economical context [Plummer et al., 2003;
Cooksey et al., 2010], classifying Italy as a low
endemic area with an overall prevalence of 2.3%
[Wilson et al., 2002]. Many studies carried out on
Chlamydia trachomatis demographic distribution in a
wide range of different geographical settings sug-
gested that age, referred usually to a cut-off of
25 years, represented the most important predictor
factor, [Nelson and Helfand, 2001; Honey et al., 2002;
Simonetti et al., 2009; Haggerty et al., 2010] recently
included in the prevention guidelines by the Centre
for Disease Control and Prevention [Workowski and
Berman, 2011].
The aim of the present study was to assess the
prevalence of Chlamydia trachomatis and HPV co-
infection in different cohorts of asymptomatic females
from a hyperendemic area for cervical cancer, in
order to estimate the grade of spread of these
infections and the association with cervical lesions.
For this purpose, DNA extracted from cervical speci-
mens was analysed for the simultaneous detection of
Chlamydia trachomatis and HPV by a high sensitive
bead-based assay supported by the Luminex
technology.
MATERIALS AND METHODS
Specimens
Cervical samples were obtained over approximately
5 months in 2012, from a group of Italian females
recruited as outpatients attending the prevention
centre for Cervical Cancer Screening Program, the
Sexually Transmitted Infections clinic and the As-
sisted Reproductive Technology centre. Cervical sam-
ples were collected using a 200mm polyethylene
Cervex brush device (Rovers Medical Devices B.V.,
Oss, The Netherlands) in 500ml of TE buffer. The top
portion uses a soft, flexible brush to obtain cell
samples, while the shape allows the top edges to
follow the contours of the cervix. The longer middle
bristles reach deep into the endocervical canal while
the shorter bristles touch both the ectocervical area
(external os) and the transformation zone (T-zone).
The cytopathological classification was performed in
accordance with the diagnostic criteria for the Be-
thesda System 2001 [Solomon et al., 2002].
Specimens were collected anonymously, coded with
indication of age and stored at 80˚C at the Virology
laboratory of the Institute for Maternal and Child
Health (IRCCS) - “Burlo Garofolo” of Trieste, Italy.
Among the 441 recruited females, 305 (mean age
36 10 years) were included in group 1 (Cervical
Cancer Screening Program) 85 (mean age 28 10
years) in group 2 (Sexually Transmitted Infections)
and 51 (mean age 37 10 years) in group 3 (Assisted
Reproductive Technology) respectively. All females
were of Caucasian origin, living in the same geo-
graphic area, referred no previous history or symp-
toms of sexually transmitted infections and were
asymptomatic for Chlamydia trachomatis or other
genital infections at the time of sampling.
The study (R.C. n˚02/11) was approved by the
Institutional Scientific Board of the IRCCS “Burlo
Garofolo”–Trieste, Italy and informed written consent
was obtained from the participants.
HPV Type-specific E7 PCR Bead-Based
Multiplex Genotyping and Chlamydia
Trachomatis Detection
DNA was extracted from 500ml of samples using a
commercial kit (High Pure PCR Template prepara-
tion Kit, Roche Applied Science, Mannheim,
Germany). The multiplex HPV type-specific E7 PCR
(IARC, Lyon, France) utilizes HPV type-specific pri-
mers targeting the E7 region for the detection of 12
high risk-HPV types (HPV-16,-18,-31,-33,-35,-39,-45,-
51,-52,-56,-58,-59), 7 possible or probable high risk-
HPV types (HPV-26,-53,-66,-68 (a and b),-70,-3,-82),
and 2 low risk-HPV types (HPV-6 and-11), with
detection limits ranging from 10 to 1,000 copies of
the viral genome. The amplicon size varies between
210 and 258 bp [Comar et al., 2012].
Two primers designed within a gene encoding for a
conserved hypothetical virulence plasmid protein
were additionally added for the amplification of
Chlamydia trachomatis. Moreover, primers for ampli-
fication of the B-globin gene were also included as
control for the quality of the template DNA. Follow-
ing PCR amplification, 10ml of each reaction mixture
was analysed by MPG using the Luminex technology
J. Med. Virol. DOI 10.1002/jmv
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(Luminex Corporation, Austin, TX) as described
previously.
In brief, HPV genotypes were detected as the
median fluorescence intensity (MFI) of at least 100
beads per bead set. The background value for each
probe was considered the MFI value resulted from
hybridization mixture without the addition PCR
product. The cut-off was computed by adding 5 MFI
to 1.1 the median background value. [Gheit et al.,
2006; Schmitt et al., 2010].
Real Time PCR for Chlamydia Trachomatis
DNA samples were further investigated by Real
Time PCR (RT-PCR) as confirmatory assay for Chla-
mydia trachomatis, detection limit of the test 10
copies/ml, using the commercial kit (CTDNA Dia.Pro,
Milan, Italia) following recommended protocol. Ampli-
fication and PCR product detection were performed
with the ABI Prism 7900 Sequence Detection system
(Applied Biosystems, Monza, Italy).
Statistical Analysis
Only cases with available and valid Chlamydia
trachomatis and HPV DNA laboratory results were
included in the present study. Statistical analyses
were performed using the IBM SPSS Statistics 20
statistical program. Age was reported as mean stan-
dard deviation (s) and discrete variables as number
and percentages. The ANOVA (Analysis of variance)
Test was performed to compare mean age values
across groups and the Chi Square Test was calculat-
ed to compare frequencies of discrete variables. The
Fisher Exact Test was applied when necessary. A
value of P 0.05 was considered statistically signifi-
cant for all tests.
RESULTS
The analysis were restricted to cervical specimens,
corresponding to 441 samples, tested positive for the
globin gene using a bead-based multiplex PCR assay
for Chlamydia trachomatis/HPV co-detection (Fig. 1).
The performance of the assay has been evaluated by
testing DNA in cervical samples. The agreement was
almost perfect for both HPV (K coefficient: 0.71)
[Comar et al., 2012] and Chlamydia trachomatis (K
coefficient: 0.98) and the reference assays using for
validation, Linear Array for HPV and RT-PCR for
Chlamydia trachomatis, respectively.
The prevalence and distributions of Chlamydia
trachomatis and HPV infections were reassumed in
Table I. In brief, the overall prevalence of infections
showed that the 9.7% (43/441) of the tested samples
were positive for Chlamydia trachomatis and the
29% (127/441) for HPV as solitary infections, while
co-infections with the two microorganisms were de-
tected in 17% (75/441) of samples. Regarding the
distribution of infections by clinical departments, the
rate of Chlamydia trachomatis detection ranged from
6% to 26%, of HPV from 6% to 40% and of Chlamydia
trachomatis/HPV co-infection from 10% to 42%. Spe-
cifically, the frequency of Chlamydia trachomatis
infection was higher in samples from females attend-
ing the Sexually Transmitted Infections centre in
comparison to those from the Cervical Cancer Screen-
ing Program and Assisted Reproductive Technology
centres (P< 0.001). Conversely, HPV was found fre-
quently in samples from Cervical Cancer Screening
Program rather than in those from Sexually Trans-
mitted Infections and Assisted Reproductive Technol-
ogy (P< 0.001). In addition, the rate of co-infection
was higher in samples from women attending the
Sexually Transmitted Infections centre, showing a
statistically significant difference (P< 0.001).
Fig. 1. The Bioplex results window: a) The histogram plots
the number of events per channel number for the selected well,
analyte(s), and channel type. An event is generated when
particles such as a bead or aggregated beads pass through the
path of the lasers. During a reading, a doublet discriminator
(DD) channel measures the amount of light scatter from
particles that flow past the red laser. The light scatter is
directly proportional to particle size. b) Bead Map co-detection
of HPV and Chlamydia trachomatis. The white areas on the
map (arrow) indicate the expected regions of the selected
analytes. Each cluster of dots that falls within a white region
represents a unique bead set (analyte) within an assay.
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The age-standardize data (cut-off 25 years) referred
to the prevalence of the two pathogens was shown in
Table II. Although, the Assisted Reproductive Tech-
nology group has not been considered since no
females aged less than 25 years attended the centre
for infertility or reproduction defects, results from
this analysis highlighted that Chlamydia trachomatis
and Chlamydia trachomatis/HPV co-infection were
associated significantly to young females (< 25 years),
independently from clinical categories (P¼ 0.02;
P¼ 0.03, respectively).
In these series, oncogenic high risk-HPV types
were present in 100% of the infected females showing
that 57.5% of the infections were attributed to HPV-
16; 16.5% to HPV-31; 15% to HPV-33; 5.5% to HPV-
18 and 5.5% to other genotypes. Interesting, a high
rate of multiple HPV infections (2 to 5 HPV types)
was observed, showing an overall prevalence of 75.6%
(96/127) of which, 58.3% (56/96) was associated to
Chlamydia trachomatis infection.
The cytopathological report was available for 92%
(407/441) of the recruited females of which 43% (175/
407) showed cytological alterations classified as low
squamous intraepithelial lesions. Considering only
females with low squamous intraepithelial lesions, a
multivariate analysis including age (cut-off 25 years)
was performed, which results have been reported in
Table III. As expected, HPV was found associated to
cervical lesions in 61% of women, independently of
age (63% in females aged  25 years and 45% in
females aged ! 25 years). HPV-16 genotype was the
most prevalent (42%), found as solitary infection in
66.6% of cases.
In this group, Chlamydia trachomatis was found in
8% of the samples, which co-infection with HPV was
detected more frequently in females aged ! 25 years
(20% vs. 1%; P< 0.001).
DISCUSSION
In the developed world, HPV testing can identify
females at risk for cervical cancer reducing cervical
cancer incidence in a cost-effective manner. High
risk-HPV types have been demonstrated in almost
100% of cervical carcinomas and persistent infection
with the same genotype increases strongly the risk of
developing high-grade pre-invasive disease.
Nevertheless, there is epidemiologic data suggest-
ing that Chlamydia trachomatis may contribute in
cervical carcinogenesis [Silins et al., 2005] although
how it synergizes with HPV in the transforming
process is still debated [Idahl et al., 2010]. It is worth
noting that due to the same modality of transmission,
Chlamydia trachomatis and HPV co-infection, is
increasing in sexually active females and therefore
early diagnosis and treatment of infected subjects is
required to prevent the spread of the infections and
possible sequelae [Verteramo et al., 2009]. In this
context, the availability of a highly sensitive and
specific molecular technique could improve the
TABLE I. Demographic Characteristics of Enrolled Females and Prevalence of CT, HPV and CT/HPV Infections
Clinical Department
Infections n˚(%)
n˚ females Mean Age"s CT HPV CT/HPV
CCSP# 305 36"10 17 (6%) 122 (40%) 30 (10%)
STI## 85 28"10 22 (26%) 5 (6%) 36 (42%)
ART 51 37"10 4 (8%) 0 (0%) 9 (18%)
Total 441 33.8"10 43 (9.7%) 127 (29%) 75 (17%)
CCSP: Cervical Cancer ScreeningProgram; STI: Sexually Transmitted Infection; ART: Assisted Reproductive Technology; CT: Chlamydia
trachomatis; HPV: Human Papillomavirus; CT/HPV: Chlamydia trachomatis and Human Papillomavirus co-infection.
STI## versus CCSP and versus ART considering CT P< 0.001.
STI## versus CCSP and versus ART considering CT/HPV P< 0.001.
#CCSP versus STI and versus ART considering HPV P< 0.001.
TABLE II. Prevalence of HPV and CT Infections in Females According to Age Cohorts (Clinical Cut-off 25 Years of Age)
and to Clinical Department
Clinical Dep
Infections  25 years Infections !25 years
n˚ females CT n˚(%) HPV n˚(%) CT/HPV n˚(%) n˚ females CT n˚(%) HPV n˚(%) CT/HPV n˚(%)
CCSP 254 8(3%) 109(43%) 10(4%) 51 9(18%)# 13(26%) 20(39%)#
STI 40 10(25%) 3(8%) 12(30%) 45 12(27%) 2(4%) 24(53%)##
ART 51 4(8%) 0(0%) 9(18%) 0 NA NA NA
Total 345 22(6.4%) 112(38%) 31(8.9%) 96 21(22%) 15(15.6%) 44(45.8%)
CCSP: Cervical Cancer Screening Program; STI: Sexually Transmitted Infection; ART: Assisted Reproductive Technology; CT: Chlamydia
trachomatis; HPV: Human Papillomavirus; CT/HPV: Chlamydia trachomatis and Human Papillomavirus co-infection.
NA: not applicable.
#CCSP considering CT P< 0.001 and CT/HPV P< 0.02.
##STI considering CT/HPV P< 0.03.
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diagnosis of these pathogens, specifically when pres-
ent at very low copies in asymptomatic high-risk
females.
In this study, a better performance in the detection
rate of Chlamydia trachomatis and HPV infection
was obtained using a highly-sensitive bead-based
multiplex PCR assay. In this cohort, the prevalence
of Chlamydia trachomatis was of 9.7% in contrast
with the national data indicating a percentage of
2.3% using routine molecular techniques [Marcone
et al., 2012], suggesting that the prevalence of low-
copy-number infections may be underestimated, spe-
cifically in asymptomatic subjects, by other assay.
In agreement, the highest prevalence of Chlamydia
trachomatis was found in young females aged less
than 25 years old (22%) although a peak of co-
infection with HPV was reached in 45.8% of them,
confirming “age” as an important demographic risk
factor in the acquisition of these infections. Of note,
Chlamydia trachomatis was found associated, in
58.3% of the cases, with a high risk-HPV genotype
suggesting a role for Chlamydia trachomatis in type-
specific HPV redetection, probably due to reactivation
of a low level of persistent oncogenic HPV as recently
reported [Shew et al., 2013]. Moreover, in young
females with a referred low grade abnormal cytology,
Chlamydia trachomatis or co-infection with HPV was
found significantly associated to the cytological status
independently of others risk factors. These findings
seem to support a role for Chlamydia trachomatis in
cell transformation, probably acting as additional risk
factor, but in line with the exerted biological effect
favouring damage of the mucosal barrier, interfer-
ence in HPV viral clearance, cell chromosome insta-
bility and inflammatory process of the upper genital
tract. [Grieshaber et al., 2006; Knowlton et al., 2011].
Given our results, although the highly sensitive
multiplex assay used in this study appear to perform
better at the analytical level than other molecular
tests, the clinical benefit remains limited to Chlamyd-
ia trachomatis infection since it could contribute to
prevention of sequelae and to a possible decrease of
incidence of pre-cancer intraepithelial lesions.
In conclusion, this survey reported new findings
about the epidemiology of Chlamydia trachomatis
and HPV co-infection in young asymptomatic females
from a hyperendemic area for cervical cancer,
highlighting the high prevalence of infection and
the significantly association with cytological
abnormalities.
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High prevalence of hpv multiple genotypes in
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Abstract
Background: Chlamydia trachomatis interaction with HR-HPV types has highlighted a central role in cervical cancer
development. The aim of this study was to investigate HPV prevalence and genotypes distribution in women at risk
for C. trachomatis infection and negative for intraepithelial lesion or malignancy.
Methods: 1071 cervical swabs were tested for C. trachomatis by Real Time PCR and genotyping by ompA gene
sequencing. Additionally, a quantitative Real time-PCR was performed to assess the expression of the C. trachomatis
Hsp60–encoding gene (Ct604 portion), linked to a persistent status of infection. HPV infection and genotypes was
investigated in C. trachomatis positive women using Luminex technology.
Results: C. trachomatis infection was detected in 53 out of 1071 (4.5%) samples, of which the 53% resulted positive
for Hsp60 gene expression. The overall prevalence of HPV infection in C. trachomatis positive samples was of 60.4%
(32/53): in 37.5% of samples was present a single genotype, while multiple genotypes infections were found in the
62.5% of them. Among women with a C. trachomatis chronic infection, 68% were HPV co-infected and the 79%
showed multiple genotypes. Should be noted that levels of C. trachomatis Hsp60 expression in HPV co-infected
women were significantly lower compared to women infected only with C. trachomatis. The C. trachomatis serotype
F was found in the majority of samples, independently of HPV infection.
Conclusions: A high prevalence of HPV multiple infections have been found in young women affected with a C.
trachomatis chronic infection. These observations suggested that the expression of CHSP60-1, interfering with both
apoptotic and cellular senescence pathways, may promote a favourable local microenvironment for HPV infection.
Keywords: Human papillomavirus, Chlamydia trachomatis, HPV multiple genotypes, Hsp60 RNA persistent infection
Background
Chlamydia trachomatis (C. trachomatis), an intracellular
bacteria characterized by a unique biphasic developmental
cycle, is the most common sexually transmitted pathogens
in women. Although C. trachomatis can cause pelvic in-
flammatory disease (PID), infertility, ectopic pregnancy,
the clinical course is usually sub-acute and poorly
symptomatic and the microorganism is rarely detected in
subjects without clinical signs of infection [1].
The ability of C. trachomatis to cause chronic persistent
infection, characterized by the permanence of microorgan-
isms in the host cells, can represent a common event [2].
During persistent status, C. trachomatis produces a large
quantity of Heat shock protein 60 (Hsp60) exhibited on the
host cell surface and released into the extracellular space
and in the bloodstream. This protein is considered a useful
marker during clinical complications since its expression
induce host chronic inflammation response [1,3,4]. Thus,
this microorganism is considered as a potent immunogen,
stimulating a rapid and intense inflammatory response in-
volving previously sensitized lymphocytes [5].
* Correspondence: manola.comar@burlo.trieste.it
†Equal contributors
1Institute for Maternal and Child Health - IRCCS “Burlo Garofolo” via dell’ Istria
65, 34100 Trieste, Italy
2Medical Science Department, University of Trieste, Piazzale Europa 1,
34100 Trieste, Italy
Full list of author information is available at the end of the article
© 2014 Seraceni et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Seraceni et al. Infectious Agents and Cancer 2014, 9:30
http://www.infectagentscancer.com/content/9/1/30
Although epidemiological data have not yet provided
consistent evidence about a real implication of C. tra-
chomatis in cervical cancer, the co-infection with
Human papillomavirus (HPV), sharing the transmis-
sion route and the same risk factors, have recently
highlighted [6-8]. A role for C. trachomatis as cofactor
was suggested, since it seems to facilitate the penetra-
tion of HPV and the progress of cervical lesions inter-
fering in the immunological response [9]. Moreover,
some authors recently detected a high-risk for the de-
velopment of cervical cancer in patients with HPV
infection and history of C. trachomatis [10]. Neverthe-
less, the prevalence and distribution of HPV genotypes
associated to C. trachomatis infection and its clinical
persistence are poorly explored.
HPVs are a family of DNA viruses that infect cutane-
ous epithelia, oral and genital mucosa. More than 100
different HPV types have been identified and charac-
terized in two risk classes on the basis of their onco-
genic potential: Low-risk (LR-HPV) types associated
with benign genital warts and High-risk (HR-HPV)
type considered the etiological agents of cervical can-
cer and other genital malignancies [11]. Approximately
15 HR-HPV genotypes are clearly associated with cer-
vical cancer of which HPV16 and HPV18 are the most
carcinogenic, since they are responsible for approxi-
mately 50% and 20% of all cervical cancers worldwide,
respectively. Multiple human papillomavirus genotypes
often coexist within cervical epithelia and are fre-
quently detected together in women with precancer
cervical lesions [12]. Nevertheless, although HPV is a
prerequisite for cervical cancer only a small number of
women exposed to this virus developed cancer, imply-
ing that other risk factors may be considered as cofac-
tors rather than independent factors. On this basis, the
characterization of HPV infection in women suffering
from C. trachomatis could be important in generating
hypotheses regarding the possible synergism of these
pathogens in cervical malignancy [13-16].
The aim of this study was to investigate HPV geno-
types distribution and the frequency of infection in
Italian women considered at risk for C. trachomatis in-
fection but negative for cervical lesions or malignancy.
Furthermore, the role of C. trachomatis chronic infection
in promoting HPV susceptibility has been evaluated.
Methods
Specimens
In 2013 year, cervical swabs (CS) specimen from 1071
women at risk for C. trachomatis infection were col-
lected at the Virology laboratory of the IRCCS-Burlo
Garofolo of Trieste, Italy, as part of C. trachomatis rou-
tine screening practices. Cervical samples were collected
using a 200 mm polyethylene Cervex brush device
(Rovers Medical Devices B.V., The Netherlands) in
500 μl of TE buffer. The study was approved by the
Institutional Scientific Board of the Institute for Mater-
nal and Child Health - IRCCS “Burlo Garofolo”–Trieste,
Italy and informed consent was obtained from each par-
ticipant in accordance with the principles outlined in the
Declaration of Helsinki.
C. trachomatis detection
Genomic DNA was extracted, after samples centrifuga-
tion, using the QIAamp DNA Blood miniKit (Qiagen,
GmbH, Germany) as indicated by the supplier, and then
stored at −80°C until analysis.
The presence of C. trachomatis DNA was detected by
Real Time PCR (RT-PCR), using a commercial kit
(CTDNA, Dia.Pro, Italia), detection limit of the assay was 1
copies/μl, to amplify a conserved region of the cryptic plas-
mid element of C. trachomatis, following recommended
protocol. The amplification and PCR product detection
were performed with the ABI Prism 7900 Sequence Detec-
tion system (Applied Biosystems, Italy).
HSp60 gene expression
C. trachomatis -RNA extraction and cDNA synthesis
An aliquot, from each CS fresh specimen (1 ml), was
centrifuged at 14.000 rpm for 15 min at 4°C and total
RNA was extracted to the pellet obtained by RNeasy
Mini kit (Qiagen GmbH, Hilden, Germany) in according
to the manufacturer’s instructions. The RNA final concen-
tration (25 μg/ml) eluted in 50 μl of distilled water, was
treated during sample processing with Dnase I (RNase-
Free DNase Set, Qiagen GmbH, Hilden, Germany), and
subsequently stored at −80, in order to avoid DNA gen-
omic contaminations.
cDNA synthesis was performed using kit SuperScript
VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA,
USA), according to manufacturer’s instructions. Briefly,
14 μl of RNA were added to a mixture containing: 5X
VILO™ Reaction Mix10, 10X Superscript Enzyme Mix
and diethyl-pyro carbonate water (DEPC-treated) until
a final volume of 20 μl and subsequently incubated at
42°C for 60 minutes and then at 85°C for 5 minutes.
cDNA synthesized was employed for quantitative RT-
PCR (qPCR).
C. trachomatis-Hsp60 qPCR
To quantify the transcript level for the C. trachomatis
portion Hsp60 gene (Ct604) in specimen, a dedicated
qPCR was used as previously described [17,18]. The
sensitivity of each assay was determined to be the lowest
dilution of DNA (2 10−4 ng/ml corresponding to one gen-
ome copies/μl) and a standard curve equations were used
to calculate the absolute copy number of gene mRNA.
Seraceni et al. Infectious Agents and Cancer 2014, 9:30 Page 2 of 7
http://www.infectagentscancer.com/content/9/1/30
In brief, the test included a serial standard curve,
negative control with PCR-grade water and a positive
control (C. trachomatis strain-TW-3). PCR reaction, in a
final volume of 20 μl, contained: 5 μl of cDNA, 2 μl LC
FastStart DNA Master SYBR Green I (Roche Molecular
Biochemicals, Germany), 5 mM MgCl2 and 0.8 μM each
primer. The thermocycling condition was: 95°C at
10 min followed by 40 cycles of 15 s at 95°C and 1 min
at 63°C. The amplification was carried out in an ABI
7900HT Fast Real Time PCR System (Applied Biosys-
tems, Italy). The concentration of unknown samples
based on their Ct values was determined with analytical
software (Software SDS 2.4; Applied Biosystems) [19].
The specificity of qPCR was further confirmed by agar-
ose gel electrophoresis analysis, which showed the ex-
pected amplification product of 161 bp in length.
C. trachomatis genotyping
C. trachomatis genotyping were performed by ompA
gene primers; positive PCR amplification products were
purified, sequenced and analysed with BLAST program
(http://www.ncbi.nlm.nih.gov/BLAST) as previously de-
scribed [20].
HPV detection and characterization
HPV was detected in CS specimens using molecular
assay supported by the Luminex technology (Luminex
Corporation, Austin, TX). HPV genotyping was per-
formed using the type specific E7 polymerase chain reac-
tion bead-based multiplex assay (TS-E7-MPG, IARC,
Lyon, France) as recently described [21]. The detection
limits of the assay ranged from 10 to 1,000 copies of the
viral genomes included in the analysis. In addition, the
β-globin gene was included, as internal positive control
[22]. To analyse a greater number of LR-HPV types,
(HPV-6,-11,-40,-42,-43,-44,-54,-61,-70), the Anyplex™ II
HPV Detection assay (Seegene Inc., Arrow diagnostics,
Italy) was additionally used in according to manufac-
turer’s instructions. A human housekeeping gene was
used as an endogenous internal control, which can en-
sure DNA purification, PCR reaction and specimen
quality (Anyplex™ user manual, Seegene 2012).
Statistical analysis
Chi Square Test was used to compare frequencies of
discrete variables: Fisher Exact Test was applied when
necessary. P value ≤ 0.05 was considered as the threshold
of statistical significance for all tests.
Results
During 2013 year, 1071 cervical swabs from women at
risk for C. trachomatis infection (mean age 35 ± 10 years;
range: from 15 to 72 years) were analysed at the Virology
laboratory of IRCCS-Burlo Garofolo, Trieste, Italy. Of
these, 829 included Outpatients (mean age 35 ± 10 years),
161 patients from Sexually Transmitted Infection centre
(STI) (mean age 30 ± 10 years) and 81 women from the
Assisted Reproductive Technology (ART) (mean age 37 ±
10 years) clinic. All women were asymptomatic for C. tra-
chomatis and other genital infections at the time of sam-
pling, with the exception of STI women showing
inflammatory symptoms. Moreover, all women were
negative for cytological alterations, in accordance with
Bethesda System 2001 diagnostic criteria [23].
In this study, as showed in Table 1, the overall preva-
lence of C. trachomatis infection was 4.5% (53/1071)
(mean age 35 years). As expected, C. trachomatis preva-
lence, stratified by the different clinical departments
and by age, was found statistically significant higher
(12.4%) in symptomatic women attending the STI cen-
ter, than in asymptomatic women from the other groups
(p < 0.001).
In women with a C. trachomatis infection the overall
prevalence of HPV was high, tested to 60.4% (32/53),
as shown in Table 2. Regarding the distribution of
HPV, the 37.5% (12/32) of the infections were consti-
tuted by a single genotype while the 62.5% (20/32) by
multiple genotypes (from 2 to 8 types), recovered more
frequently in younger women (mean age 24 years)
(Figure 1).
The analysis of HPV genotypes, reassumed in the
Figure 2, showed that HPV-42 and HPV-31 represented
the most frequently detected genotypes, standing at 28%
and 22%, respectively. Moreover, in these women, the
Table 1 Prevalence of CT distribution in women at risk of
infection by clinical department and mean age
Clinical Department n° women Mean Age ± ơ CT n° + (%)
Outpatients 829 35 ± 10 29 (3.5%)
STI 161 30 ± 10 20 (12.4%)
ART 81 37 ± 10 4 (4.9%)
Total 1071 35 ± 10 53 (4.5%)
STI: Sexually Transmitted Infection; ART: Assisted Reproductive Technology;
CT: C. trachomatis.
Table 2 HPV co-infection distribution in women with
CT infection
CT POS HPV HPV single
infection
HPV multiple
infections*
N° N°POS/TOT N°POS/TOT N°POS/TOT
(%) (%) (%)
53 32/53 12/53 20/53
(60.4) (22.6) (37.7)
*(from 2- to 8 genotypes); CT: C. trachomatis; HPV: Human papillomavirus.
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genotypes HPV-39,-53,-56,-58 were present only as single
infection while the genotypes HPV-6-51-59-66 were de-
tected together in 31% (10/32) of the recovered infections.
In order to characterize the chlamydial phase of in-
fection, the mRNA expression of the Hsp60 gene
showed that the 53% (28/53) of the women with C. tra-
chomatis were suffering from a chronic infection
(Table 3). Of these women (mean age 26 years), the 68%
(19/28) resulted co-infected with HPV. In particular, the
79% (15/19) presented multiple infections and the 21%
(4/19) single infections. Moreover, the level of Ct-Hsp60
expression was found significantly lower (±396 copy/μl)
in women co-infected with HPV compared to women
infected only with C. trachomatis (±862 copies/μl). The
evidence for viable organisms and not just residual
DNA from a previous infection was supported to high
correlation between DNA and RNA results (data not
shown), considering that, the expressed gene should be
linked to the C. trachomatis persistence.
The classification of C. trachomatis serotypes through
the ompA gene amplification and subsequent sequen-
cing, performed in available samples, had revealed a high
frequency of serotype F, independently of chlamydial
status or HPV infection.
Discussion
Several epidemiological studies have stated a positive asso-
ciation between C. trachomatis and HPV-related cervical
diseases. The co-presence of C. trachomatis and HPV was
reported in cervical precancerous lesions, and high levels
of specific IgG antibodies or DNA of C. trachomatis were
recovered in HPV positive patients [6,14,15]. However, the
exact relationship between C. trachomatis and HPV infec-
tion is still not completely understood.
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Figure 1 HPV genotypes distribution detected in C. trachomatis positive women, according to single versus multiple concurrent
infection status. HR: High risk; prHR: Presumable High risk; LR: Low risk.
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Figure 2 Prevalence of HPV genotypes detected in C. trachomatis co-infected women (n° and%). HR: High risk; prHR: Presumable High risk;
LR: Low risk.
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In the present analysis, we evaluated the distributions
of HPV DNA-positive infections analysing a large num-
ber of specimens collected as part of routine screening
practices for C. trachomatis prevention. For the first
time, estimates are provided on the prevalence of HPV
infections and about genotype distribution in women
with a chronic C. trachomatis infection; this work has
never been assessed before. Data from our study showed
that the 60.4% of women with a diagnosis of C. tracho-
matis infection and in absence of cervical lesions, re-
sulted co-infected with one or more HPV genotypes. To
note, the 53% of them showed a chronic infection and,
HPV was found more frequently associated (68%) to
this specific chlamydial status. Moreover, a consistent
portion of these women (79%) resulted to be infected
with multiple HPV genotypes. To note, HPV multiple
infections including specific genotypes such as HPV-6-
51-59-66, was reported in the 31% of these women sup-
porting evidence that the presence of one HPV type does
not increase the likelihood of acquiring further infections,
but that, HPV multiple infections might be the result of
the local immune system impairment [8,24-31]. In our
screening population, the median age of women with 2 to
8 HPV genotypes was 24 years, according to recent data
[32,33].
In our series, HPV-31 and HPV-42 represented the
genotypes more frequently detected, testing at 28% and
22%, respectively. The overall prevalence of these ge-
notypes, with a smaller estimated oncogenic poten-
tials than HPV-16, were usually lower in HPV
screening Italian women (13.8% and 0.3%,) [34,35].
While, conversely, HPV-16 (30.7%) [34] was found
only in the 9%.
In the natural history of C. trachomatis, a chronic
infection is referred as a stop in development of
chlamydial cycle, with aberrant bodies formation, and
this state is characterized by high transcriptional
activity [36].
In this study, the expression of Hsp60 gene, a marker
of chronic infection, has been found significantly lower
in HPV co-infected women compared to women in-
fected only with C. trachomatis. Discussion on this
finding can be merely speculative, suggesting that the
maintenance of a steady-state level of transcription of
Hsp60 gene could favour a balance between the Hsp60
induced pro-inflammatory microenvironment and HPV
coexistence [14].
The chronic inflammation caused by C. trachomatis
increases oxidative stress proteins that seem to trigger
HPV cell entrance, and replication or enhance DNA
breaks that may promote viral integration [9,14,16].
Although it has been suggested that the concomitant
presence of HPV viral oncoproteins during Hsp60
expression may lead to the ability to survive apoptotic
stimuli, uncontrolled proliferation and, finally neoplas-
tic transformation, in this study specific HPV multiple
genotypes were found associated to C. trachomatis
chronic status, independently of the genotypes risk
[37,38].
Conclusions
In conclusion, the results of the present investigation
provide evidence for the notion that a high prevalence of
multiple HPV infections has been associated with C. tra-
chomatis chronic infection in young women without cer-
vical lesions. In addition, specific HPV genotypes seem
to be more frequently associated to C. trachomatis. This
data may deserve further consideration, owing to accu-
mulate evidence that the chlamydial chronic status could
contribute to favour specific HPV genotypes represent-
ing possible implications for the prevention of cervical
cancer.
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Table 3 RNA expression of the CT-Hsp60 gene in relation
to the presence or absence of HPV infection
CT-Hsp60 RNA
(+) (−)
N°/TOT (%) 28/53 (53) 25/53 (47)
HPV + n° (%) 19/28 (68)* 13/25 (52)
HPV- n° (%) 9/28 (32) 12/25 (48)
*4/19 (21%) HPV single infection and 15/19 (79%) HPV multiple infections.
CT: C. trachomatis; Hsp60: Heat shock protein 60; HPV: Human papillomavirus.
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